

# NKR\_38\_opdat\_Rehabilitering af patienter med prostatakræft: Superviseret træning- metaanalyse. København: Sundhedsstyrelsen, 2021.

## Review information

### Authors

Sundhedsstyrelsen<sup>1</sup>

<sup>1</sup>[Empty affiliation]

Citation example: S. NKR\_38\_opdat\_Rehabilitering af patienter med prostatakræft: Superviseret træning- metaanalyse. København: Sundhedsstyrelsen, 2021.. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

## Characteristics of studies

### Characteristics of included studies

#### Bjerre 2019

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial</p> <p><b>Study grouping:</b> Parallel group</p>
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 67.8 (6.2)</li> <li>● Time since diagnosis in years, mean (SD): 3.0 (2.7)</li> <li>● Number of participants on ADT (%): 46 (42), separate data for the ADT population.</li> <li>● Time on ADT in days, median (IQR): 512.5 days (208-881)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 69.0 (6.2)</li> <li>● Time since diagnosis in years, mean (SD): 3.8 (3.9)</li> <li>● Number of participants on ADT (%): 41 (39), separate data for the ADT population.</li> <li>● Time on ADT in days, median (IQR): 580 days (235-1089)</li> </ul> <p>Overall</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 68.4 (6.2)</li> <li>● Time since diagnosis in years, mean (SD): 3.4 (3.4)</li> <li>● Number of participants on ADT (%): 87 (41)</li> <li>● Time on ADT in days, median (IQR): 520 days (213-982)</li> </ul> <p><b>Included criteria:</b> Patients diagnosed with prostate cancer; Age ≥ 18 years; Able to read and complete questionnaires in Danish; Signed informed consent.</p>

	<p><b>Excluded criteria:</b> &lt; 6 weeks prostatectomy; Football training not allowed by primary physician; Hip or spine bone mineral density &lt; -2.5 T-score.</p> <p><b>Intervention Characteristics</b> Intervention</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> Participants allocated to the intervention group will be offered one hour of recreational football twice weekly. The football training sessions consist of a 20-min warm-up based on the FIFA11+ concept, though modified to suit older players. Next, participants will spend 20 min practising dribbling, passing and shooting. The training sessions will then end with 20 min of 5-7-a-side football. Two coaches recruited from the local football club will be in charge of all training sessions. The coaches are expected to have experience as either a player or coach but no other formal qualifications are required. The coaches will be required to have passed a first-aid course and to complete a 10-h course involving lectures on PCa treatment, patient experiences of PCa and a manual describing the content of the training, including the FIFA 11+ concept intended to prevent injuries. Participants will be told to avoid hard tackles and other actions that carry a risk of injury. In the event of injuries participants will remain in their allocated group and will be encouraged to participate in football practice again after recovery. Adherence to the intervention will be recorded by the coaches. Participants allocated to football training will be able to track their individual adherence and compare it to an average adherence rate of participants in the football group.</li> <li>● <b>Dose:</b> 60 mins, twice weekly</li> <li>● <b>Duration:</b> 6 months</li> <li>● <b>Time on ADT in days, median (IQR):</b> 512.5 (208-881)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> Participants allocated to the control group will receive a phone-based counselling session (5-15 min) as part of the information on group allocation, as well as information via email on the current physical activity guidelines.</li> <li>● <b>Dose:</b> Not applicable</li> <li>● <b>Duration:</b> 6 months</li> <li>● <b>Time on ADT in days, mean (SD):</b> median (IQR) 580 (235-1089)</li> </ul>
<p><b>Outcomes</b></p>	<p><b>General livskvalitet (quality of life), SF 36, mental component, mean change (95% CI)</b></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> SF 36, mental component</li> <li>● <b>Range:</b> 0-100</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Change from baseline</li> </ul> <p><b>General livskvalitet (quality of life), SF 36, physical component, mean change (95% CI)</b></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> SF 36, physical component</li> <li>● <b>Range:</b> 0-100</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Change from baseline</li> </ul>

Diagnosespecifik livskvalitet (disease specific quality of life), Functional Assessment of Cancer Therapy Prostate (Fact P), mean change (95% CI)

- **Outcome type:** Continuous Outcome
- **Reporting:** Partially reported
- **Scale:** Functional Assessment of Cancer Therapy Prostate
- **Range:** 0-156
- **Unit of measure:** Points
- **Direction:** Higher is better
- **Data value:** Change from baseline

*Fysisk funktion (physical function)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

*Muskelstyrke (muscle strength)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

*Vo2 max (Vo2 peak)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

*Depression (depression)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

*Hjertekarsygdom (cardiovascular diseases)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Diabetes (diabetes)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Frakturer (fractures) antal personer med frakturer*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Fully reported
- **Scale:** Dichotomous, Frakturer ja/nej
- **Unit of measure:** Antal personer der får fraktur
- **Direction:** Lower is better
- **Data value:** Endpoint

*Træningsrelaterede skader (Exercise related injuries) antal skader i alt*

- **Outcome type:**
- **Reporting:** Fully reported
- **Scale:** Antal træningsrelaterede skader i alt

	<ul style="list-style-type: none"> <li>● <b>Unit of measure:</b> Antal personer med</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value :</b> Endpoint</li> </ul> <p><i>Frafald (dropouts) antal personer</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, Frafald ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer der falder fra</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value :</b> Endpoint</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> The FCPC Trial is supported by TrygFonden and research grants from the Danish Cancer Society. The Musculoskeletal Statistics Unit at the Parker Institute (RC) is supported by grants from the Oak Foundation. Julie Midgaard is supported by the University Hospitals Centre for Health Research</p> <p><b>Country:</b> Denmark</p> <p><b>Authors name:</b> Eik Bjerre</p> <p><b>Institution:</b> University Hospitals Centre for Health Research (UCSF), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</p> <p><b>Email:</b> eb@ucsf.dk</p> <p><b>Address:</b> University Hospitals Centre for Health Research (UCSF), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</p>
<b>Notes</b>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Patients were randomly allocated to either a football group (FG) or a usual care group (UG) according to a computer-generated list of random numbers after all baseline assessments were completed."
Allocation concealment (selection bias)	Low risk	Quote: "A statistician not otherwise involved in the trial generated separate lists with a 1:1 ratio and varying block sizes (n = 4–8) stratified for each center and treatment category (receiving ADT or not) using SAS. The allocation was concealed from trial personnel as the statistician received a password-protected email from the trial management system (EasyTrial®) with an upload function for the allocation sequence. After participants were enrolled by trial personnel at each hospital, the trial manager telephoned participants who had provided written informed consent and undergone all baseline measurements."
Blinding of participants and personnel (performance bias)	High risk	Quote: "Randomization was done using the web-based trial management system, and the participants were told which group they were allocated to. Given the nature of the intervention, neither participants nor coaches were blinded."
Blinding of outcome assessment (detection bias)	High risk	Quote: "Blinding was implemented for objective outcomes, so personnel performing the dual-energy X-ray absorptiometry (DXA) assessments had no information on the group allocation." Judgement Comment: High risk for subjective outcomes (quality of life) Low risk for objective putcomes (Muscle strength, physical function, fractures) Critical outcome is based on self-assessment.

Incomplete outcome data (attrition bias)	Low risk	Quote: "The main analyses of the primary, secondary, and safety outcomes were performed according to the intention-to-treat (ITT) principle." Judgement Comment: Low and balances number of dropouts in the groups and reasons stated.
Selective reporting (reporting bias)	Low risk	Quote: "No changes were made during the conduct of the trial in relation to the original protocol [18] or trial registration." Judgement Comment: Protocol available, all outcomes of interest stated in the protocol are reported.
Other bias	Low risk	The study appears to be free of other sources of bias. The study appears to be free of other sources of bias. All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and received no support from any organization for the submitted work. Erik Dybbøe Bjerre, Klaus Brasso, Anders Bojer Jørgensen, Thomas Hindborg Petersen, Alexandra Röthlin Eriksen, Anders Tolver, Jesper Frank Christensen, Mads Hvid Poulsen, Søren Sørensen Madsen, Peter Busch Østergren, Michael Borre, Christoffer Johansen, Mikael Rørth, and Julie Midtgaard have had no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years. Peter Krstrup has received funding for other research activities from the DBU, Union of European Football Associations (UEFA) and FIFA in the previous 3 years. No other relationships or activities could have influenced the submitted work.

**Bourke 2014**

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial</p> <p><b>Study grouping:</b> Parallel group</p>
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>Træning</p> <ul style="list-style-type: none"> <li>● Age - Mean(sd): 71(6)</li> <li>● Height - cm: 173.1(6.8)</li> <li>● Weight - kg: 87.8(14.0)</li> <li>● BMI - kg/m<sup>2</sup>: 29.3(4.4)</li> <li>● Number of participants on ADT (%): 50 (100)</li> <li>● Time on ADT in months, mean (SD):33 (33)</li> </ul> <p>Kontrol (vanlig beh)</p> <ul style="list-style-type: none"> <li>● Age - Mean(sd): 71(8)</li> <li>● Height - cm: 173.3(7.1)</li> <li>● Weight - kg: 84.6(13.5)</li> <li>● BMI - kg/m<sup>2</sup>: 28.1(4.1)</li> <li>● Number of participants on ADT (%): 50 (100)</li> <li>● Time on ADT in months, mean (SD): 30 (30)</li> </ul> <p><b>Included criteria:</b> Eligible men were sedentary (ie, exercising &lt; 90 min per week at a moderate intensity) and receiving continuous ADT for a minimum of 6 months prior to recruitment, with planned long-term retention on ADT.</p> <p><b>Excluded criteria:</b> Men with unstable angina, uncontrolled hypertension, recent myocardial infarction, pacemakers, and painful or unstable bony metastases were excluded.</p>

**Interventions**

**Intervention Characteristics**

Træning

- *Description*: The intervention was a combined tapered exercise and dietary advice intervention delivered with integrated behaviour change support. Men attended a dedicated rehabilitation suite to undertake aerobic and resistance exercise, in groups up to five, supervised by an exercise physiologist. The aerobic exercise prescription was 30 min at an intensity of 55–85% of age predicted maximum heart rate or 11–13 on the Borg Rating of Perceived Exertion scale [1], using stationary cycles, rowing ergometers, and treadmills. Between two and four sets and 8–12 repetitions (reps) of resistance exercises (cable machines or free weights) targeting large skeletal muscle groups (quadriceps, deltoids, pectorals, latissimus dorsi, hamstrings) beginning at an intensity of 60% of one rep max with progression through increasing sets and reps before weight was increased. During the supervised sessions, emphasis was placed on providing instruction on the correct performance of exercises, effective technique through instruction and demonstration, and individual capability, with guidance on exercise intensity monitoring by using heart rate and perceived exertion. This was undertaken twice a week from weeks 1–6, and once per week from weeks 7–12. During the first 6 wk, men were also asked to undertake at least one self directed independent exercise session (eg, brisk walking, cycling, and gym exercise) for at least 30 min using the skills taught in the supervised sessions such as intensity monitoring using the Borg scale and correct technique during resistance exercise. This requirement was increased to twice per week during weeks 7–12. Goals for these sessions were set with participants and included review and feedback at each following session. During sessions the facilitator aimed to address any concerns the individual had about exercise, highlighting what the benefits might be and providing encouragement and verbal reinforcement for effort. Adherence to supervised exercise sessions was assessed by attendance records, heart rate, and Borg ratings. Independent exercise adherence was assessed via patient log books, which were also used in sessions to reflect achievement of exercise goals and monitor activity [2]. To help improve adherence, a behavioural component included exploring with patients barriers to exercise and strategies to help them incorporate regular physical activity in their daily lives, discussion around what social support structures were available to them and how to use them, and which types of physical activity they preferred to engage in. In addition to exercise training, participants were encouraged to improve their diet over the course of the intervention. All men were provided with a nutrition advice pack advocating reduction of saturated fats and refined carbohydrates, increasing dietary fibre and fruit and vegetable intake, and moderating the use of alcohol. Small-group healthy eating seminars, lasting approximately 15–20 min, were carried out every 2 wk throughout the 12-wk intervention, facilitated by the study researcher. Participants were helped to think of areas of their diet they would like to improve and were encouraged to set weekly goals towards achieving these targets. Men shared experiences of trying to change dietary habits and highlighted areas of success and issues they were finding hard to address. These experiences were then explored within the group. The group facilitator ensured that the advice pack was referred to appropriately to assist problem solving. The sessions were concluded with a verbal re negotiation of dietary goals based on the session feedback if it was appropriate. No restriction was placed on dietary habits for any trial participant.

- *Intensity*:

- *weekly training sessions*: This was undertaken twice a week from weeks 1–6, and once per week from weeks 7–12

Kontrol (vanlig behandling)

- *Description*: Men randomised to usual care were followed up in the urology clinic and seen by an oncology nurse specialist and urologist. The treating physicians were informed that the man was participating in a lifestyle intervention study and further information would be available on application

- *Intensity*: No restrictions were placed on exercise/dietary behaviours over the period of the study

- *weekly training sessions*: Not applicable

## Outcomes

*Livskvalitet, diagnose specifik*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** FACT-P
- **Range:** 0-156
- **Unit of measure:** points
- **Direction:** Higher is better
- **Data value:** Endpoint
- **Notes:** outcome data hentet fra aflæsning på fig. 3 N hentet fra Fig1 flowchart. SD er "normal sd" for FACT-P (ikke hentet fra artikel)

*Fysisk funktion*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

*Hjerte-kar sygdom*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Depression*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

*Diabetes*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Muskelstyrke*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

*Iltoptagelse (Vo2) Aerobic exercise tolerance*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** Aerobic exercise tolerance
- **Unit of measure:** Seconds
- **Direction:** Higher is better
- **Data value:** Endpoint

*Fraktur*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Fully reported
- **Unit of measure:** Numbers
- **Direction:** Lower is better
- **Data value:** Endpoint

	<p>Bivirkninger, træningsrelaterede</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Unit of measure:</b> Number of participants with skeletal related adverse events.</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p>Frafald, alle årsager</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Unit of measure:</b> Numbers</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<p><b>Identification</b></p>	<p><b>Sponsorship source:</b> None reported  <b>Country:</b> UK  <b>Setting:</b> Outpatient urology clinics in UK  <b>Comments:</b> Trial registration: ISRCTN88605738.  <b>Authors name:</b> Liam Bourke  <b>Institution:</b> Department of Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK  <b>Email:</b> d.j.rosario@sheffield.ac.uk  <b>Address:</b> Academic Urology Unit, K Floor, Department of Oncology, Royal HallamshireHospital, Glossop Road, University of Sheffield, Sheffield S10 2JF, UK</p>
<p><b>Notes</b></p>	

Risk of bias table

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "Randomisation was undertaken (1:1) by a senior academic independent of the study, at the patient level using nQuery statistical software".
Allocation concealment (selection bias)	Low risk	Quote: "Randomisation was undertaken (1:1) by a senior academic independent of the study, at the patient level using nQuery statistical software".
Blinding of participants and personnel (performance bias)	High risk	No information of blinding of participants and health care professionals. Blinding not feasible.
Blinding of outcome assessment (detection bias)	High risk	Quote: "Functional outcomes were assessed by a trained technician blinded to group allocation". High risk for self-reported outcomes (quality of life)
Incomplete outcome data (attrition bias)	Low risk	Equal drop out in the two groups, reasons stated.



Selective reporting (reporting bias)	High risk	Referenece to a protocol, Muscle strength stated as secondary outcome in the protocol but not reported
Other bias	Low risk	The study appears to be free of other sources of bias

**Cormie 2015**

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial</p> <p><b>Study grouping:</b> Parallel group</p>
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>Træning</p> <ul style="list-style-type: none"> <li>● Age in years - Mean(sd): 69.9 (5.5)</li> <li>● Time since diagnosis, months, mean (SD): 16.6 (27.0)</li> <li>● BMI - kg/m<sup>2</sup>: 29.3 (4.5)</li> <li>● Number of participants on ADT (%): 32 (100)</li> <li>● Time on ADT in days, mean (SD): 6.2 (1.16)</li> </ul> <p>Kontrol (vanlig behandling)</p> <ul style="list-style-type: none"> <li>● Age - Mean(sd): 67.1 (7.5)</li> <li>● Time since diagnosis, months, mean (SD): 10.4 (14.4)</li> <li>● BMI - kg/m<sup>2</sup>: 29.6 (2.6)</li> <li>● Number of participants on ADT (%): 31 (100)</li> <li>● Time on ADT in days, mean (SD): 5.6 (2.0)</li> </ul> <p><b>Included criteria:</b> One hundred and twenty-six men aged 46–80 years scheduled to commence ADT for the treatment of prostate cancer were referred by oncologists and urologists in Perth, Western Australia from June 2011 through to October 2012, and screened for participation in the study (Fig. 1). Participants were not involved with any other clinical trial or exercise trial. Participants had a histological diagnosis of prostate cancer, were beginning treatment with leuprorelin acetate depot (Lucrin®), were anticipated to remain on ADT for at least the next 3 months and obtained written medical clearance from their physician (GP).</p> <p><b>Excluded criteria:</b> Patients were excluded if they had previously received ADT, had established bone metastatic disease, were unable to walk 400 m unassisted or had musculoskeletal, cardiovascular and/or neurological disorders that could inhibit them from exercising (as determined by the patient's physician).</p>
<b>Interventions</b>	<p><b>Intervention Characteristics</b></p> <p>Træning</p> <ul style="list-style-type: none"> <li>● Description:</li> </ul> <p>The exercise intervention involved twice weekly exercise sessions for 3 months in one of six exercise clinics across Perth and regional Western Australia (Bunbury). Sessions were conducted in small groups of 8–10 participants supervised by accredited exercise physiologists. The sessions were ≈60 min in duration and involved moderate–high intensity aerobic and resistance exercises, as well as standard warm-up and cool-down periods. The aerobic exercise component included 20–30 min of cardiovascular exercise using various modes, e.g. walking or jogging on a treadmill, cycling or rowing on a stationary ergometer or exercising on a cross trainer machine. Target intensity was set at approximately 70–85% of estimated maximum heart rate. The resistance exercise component involved eight exercises that targeted the major upper and lower body muscle groups (leg press, leg extension, leg curl, calf raise, chest press, latissimus dorsi pull-down, biceps curl and triceps extension). Intensity was manipulated from 6–12 repetition</p>

maximum (RM); i.e. the maximal weight that can be lifted 6–12 times, which is equivalent to ≈60–85% of one repetition maximum [1RM]) using 1–4 sets per exercise. To ensure the progressive nature of the programme, participants were encouraged to work past the specific RM prescribed and the resistance was increased by a 5–10% increment for the next set/training session if the participant exceeded the target RM. Prescription of both aerobic and resistance exercise components was progressive and modified according to individual response. Session rating of perceived exertion (RPE) was recorded immediately after the completion of each exercise session to monitor the perceived intensity of the exercise [28]. Participants were encouraged to supplement the supervised exercise sessions with home-based aerobic exercise with the aim of accumulating a total of at least 150 min of moderate intensity aerobic exercise each week. The exercise intervention was designed in accordance with international guidelines [29].

Kontrol (vanlig behandling)

- *Description:*

Participants randomised to the usual-care group received no intervention but were offered the exercise programme after the completion of the intervention period. All participants maintained standard medical care for the treatment of prostate cancer and were instructed to maintain their customary activity and dietary patterns throughout the intervention period.

**Outcomes**

*Livskvalitet, Helbredsrelateret*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** SF-36, Physical health composite and mental health composite
- **Range:** 0-100
- **Unit of measure:** points
- **Direction:** Higher is better
- **Data value:** Endpoint

Fysisk funktion

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** Repeated chair raise, 5 repetitions
- **Unit of measure:** Seconds
- **Direction:** Lower is better
- **Data value:** Endpoint

Muskelstyrke

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** Leg press, 1 RM
- **Unit of measure:** Kg
- **Direction:** Higher is better
- **Data value:** Endpoint

*Iltoptagelse (Vo2)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** Vo2 max
- **Unit of measure:** ml/Kg/min

	<ul style="list-style-type: none"> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Hjerfte-kar sygdom</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Depression</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Brief symptom inventory BSI-18</li> <li>● Range 0-24</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Diabetes</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Fraktur</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Unit of measure:</b> Numbers</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Bivirkninger, træningsrelaterede</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Unit of measure:</b> Numbers</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Frafald, alle årsager</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Unit of measure:</b> Numbers</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> The study was funded by Abbvie Pty Ltd.  <b>Country:</b> Australia  <b>Setting:</b> Patients diagnosed with prostate cancer were referred by oncologists and urologists in Perth, Western Australia.</p>

<b>Notes</b>	<p><b>Comments:</b> ACTRN12610000691044; <a href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335822">https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=335822</a>.</p> <p><b>Authors name:</b> Prue Cormie</p> <p><b>Institution:</b> Edith Cowan University Health and Wellness Institute, Edith Cowan University</p>
--------------	---

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Adequately performed sequence. Quote: "participants were randomised in an allocation ratio of 1:1 using a random assignment computer program"
Allocation concealment (selection bias)	Low risk	Quote: "The project coordinator and exercise physiologists involved in assigning participants to groups were 'blinded' to the allocation sequence"
Blinding of participants and personnel (performance bias)	High risk	Not possible to blind
Blinding of outcome assessment (detection bias)	High risk	insufficient reported. High risk for self-repted outcomes (Quality of life)
Incomplete outcome data (attrition bias)	Low risk	Intervention: 1/32, control: 7/31, ITT analyses
Selective reporting (reporting bias)	Low risk	None detected
Other bias	Low risk	No other sources of bias

**Dawson 2018**

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial</p> <p><b>Study grouping:</b> Parallel group</p>
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 68.6 (8.4)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 28.5 (4.7)</li> <li>● Time since diagnosis in years, mean (SD): 4.7 (5.1)</li> <li>● Number of participants on ADT (%): 16 (100)</li> <li>● Time on ADT in months, mean (SD): 14.6 (15.4)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 66.3 (9.0)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 26.1 (4.0)</li> <li>● Time since diagnosis in years, mean (SD): 4.7 (4.9)</li> <li>● Number of participants on ADT (%): 19 (100)</li> </ul>

	<ul style="list-style-type: none"> <li>● <i>Time on ADT in months, mean (SD):</i> 12.7 (11.6)</li> </ul> <p><b>Included criteria:</b> Current treatment with gonadotrophin-releasing hormone (GnRH) agonist/antagonist with or without anti-androgen for at least 12 weeks, or prior treatment of GnRH agonist/antagonist with serum testosterone concentration &lt; 50 ng·dl<sup>-1</sup> at baseline and for the study duration. For patients not currently receiving ADT, an additional screening of testosterone &lt; 50 ng·dl<sup>-1</sup> was performed</p> <p><b>Excluded criteria:</b> Chemotherapy or radiation within 4 weeks of enrollment; Major surgery within 6 months; Coronary or vascular event in the last year; Current participation in a structured exercise program.</p>
<p><b>Interventions</b></p>	<p><b>Intervention Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● <i>Description:</i> TRAIN (TRAIN+TRAINPRO = EXE group): TRAINPRO and TRAIN groups performed resistance training 3 days per week for 12 weeks with an accredited exercise trainer at the USC Clinical Exercise Research Center. The resistance training program met the American Cancer Society's (ACS) guidelines for strength training and the Compendium of PhysicalActivity's classification for vigorous intensity. Each session was ~ 50 min in duration and began with a 5 min dynamic warmup of body weight exercises that targeted the muscle groups used in the resistance training routine (Table 1). The weekly training volume was divided such that each muscle group was trained twice per week, with lower body and trunk trained on the first day, lower and upper extremities on the second day, and upper body and trunk on the third day. The training routine included 7 machine-based exercises (leg press, leg curl, leg extension, chest press, shoulder press, seated row, lat pulldown) and 3 trunk exercises (plank, hip bridge, dead bug). Because metastatic patients were included, alternative exercises were offered to patients with pre-existing pain due to affected skeletal sites (Table 1). This modular approach has been utilized in previous investigations conducted in patients with bone metastatic disease. Every session concluded with 5 min of static stretching, where hip flexors/extensors were stretched on lower body and total body days, and shoulder flexors/extensors were stretched on upper body and total body days. The resistance exercise load was systematically progressed using a periodization model as previously described, with 3 sets of each exercise performed and rest periods held constant at 1 min between sets. The periodization model consisted of a 4-week muscular endurance mesocycle and an 8-week hypertrophy mesocycle, where load and repetitions were varied over the course of the intervention. Because brief periods of overreaching were expected due to each load increase, repetitions were tapered by 2 in the second week of each microcycle to maximize adaptations without overtraining. The progression cycle was as follows: Weeks 1-2:60% 1RM, 15 repetitions; Weeks 3-4: 65-67%, 15-12 repetitions; Weeks 5-6: 70% 1RM, 12-10 repetitions; Weeks 7-8:75% 1RM, 10-8 repetitions; Weeks 9-10: 80% 1RM, 10-8 repetitions; Weeks 11-12: 83% 1RM, 8 repetitions. Participants were trained to fatigue with each set, where verbal encouragement and light spotting for completion of all repetitions were provided when necessary. In addition to the described training, the TRAINPRO were given 50 g·day<sup>-1</sup> of whey protein isolate (EnergyFirst®, Manhattan Beach, CA) for 12 weeks. The 50 g daily supplement was divided into two 25 g doses, with each 25 g dose containing 112.5 kcal, 25 g protein (2 g leucine), 0 g fat, and 3.75 g carbohydrate. For TRAINPRO participants,one dose was given immediately after the exercise session to optimize post-exercise anabolic stimuli.Participants completed a protein diary, which was collected on a weekly basis.</li> <li>● <i>Dose:</i> 50 min, 3 days per week</li> <li>● <i>Duration:</i> 12 weeks</li> <li>● <i>Time on ADT in months, mean (SD):</i> EXE: 14.6 (8.4)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <i>Description:</i> STRECTH (STRECTH + PRO = NoEXE group): PRO and STRECTH groups performed a home-based flexibility program 3 times per week for 12 weeks, then were offered the exercise program at the end of the study. Each home-based stretching session lasted 5 min and matched the stretches performed by TRAIN and TRAINPRO groups. PRO and STRECTH groups were given a stretching band, a booklet detailing the exercises, and were asked to complete weekly records of flexibility compliance and other exercises performed outside the study with a monetary compensation provided at midpoint and post-intervention. In addition to the home program, the PRO were given 50 g·day<sup>-1</sup> of whey protein isolate (EnergyFirst®, Manhattan Beach, CA) for 12 weeks. The 50 g daily supplement was divided into two 25 g doses, with each 25 g</li> </ul>

	<p>dose containing 112.5 kcal, 25 g protein (2 g leucine), 0 g fat, and 3.75 g carbohydrate. Participants completed a protein diary, which was collected on a weekly basis.</p> <ul style="list-style-type: none"> <li>● <b>Dose:</b> See above</li> <li>● <b>Duration:</b> 12 weeks</li> <li>● <b>Time on ADT in months, mean (SD):</b> NoEXE: 12.7 (11.6)</li> </ul>
<p><b>Outcomes</b></p>	<p><i>Diagnosespecifik livskvalitet (disease specific quality of life), Functional Assessment of Cancer Therapy General (Fact G), mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Functional Assessment of Cancer Therapy General</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Diagnosespecifik livskvalitet (disease specific quality of life), Functional Assessment of Cancer Therapy Prostate (Fact P), mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Functional Assessment of Cancer Therapy Prostate</li> <li>● <b>Range:</b> 0-156</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Fysisk funktion (physical function) 400 meter gangtest, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> 400 meter gangtest</li> <li>● <b>Unit of measure:</b> Seconds</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Fysisk funktion (physical function), timed up and go, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Timed up and go</li> <li>● <b>Unit of measure:</b> Seconds</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Muskelstyrke (muscle strength) Leg press, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Leg press</li> </ul>

- **Unit of measure:** Kg
- **Direction:** Higher is better
- **Data value:** Endpoint

*Muskelstyrke (muscle strength), Leg extension, mean final (SD)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** Leg extension
- **Unit of measure:** Kg
- **Direction:** Higher is better
- **Data value:** Endpoint

*Vo2 max (Vo2 peak)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

*Depression (depression) Epidemiologic Studies depression Scale (CES-D), mean final (SD)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** Epidemiologic Studies depression Scale (CES-D)
- **Range:** 0-60
- **Unit of measure:** Points
- **Direction:** Lower is better
- **Data value:** Endpoint

*Hjertekarsygdom (cardiovascular diseases)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Diabetes (diabetes)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Frakturer (fractures) antal personer med*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Fully reported
- **Scale:** Dichotomous, Frakturer ja/nej
- **Unit of measure:** Antal personer der får fraktur
- **Direction:** Lower is better
- **Data value:** Endpoint

*Træningsrelaterede skader (Exercise related injuries) antal personer med*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Fully reported
- **Scale:** Dichotomous, Træningsrelaterede skader ja/nej

	<ul style="list-style-type: none"> <li>● <b>Unit of measure:</b> Antal personer med træningsrelaterede skader</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Frafald (dropouts) antal personer</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Frafald</li> <li>● <b>Unit of measure:</b> Antal personer der falder fra</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<p><b>Identification</b></p>	<p><b>Sponsorship source:</b> JKD received financial support from the National Strength and Conditioning Association and the California State University, which was used to support the exercise intervention, data collection and analysis. CJL is funded by SC CTSI UL1TR001855, which supported her role in data interpretation and manuscript review. CMD is funded by NIH/NCI K07CA160718, which supported her role in study management, analysis, and manuscript review.</p> <p><b>Country:</b> USA</p> <p><b>Authors name:</b> Jacqueline K. Dawson</p> <p><b>Institution:</b> Division of Biokinesiology and Physical Therapy, Ostrow School of Dentistry, University of Southern California</p> <p><b>Email:</b> kiwata@alumni.usc.edu</p> <p><b>Address:</b> Division of Biokinesiology and Physical Therapy, Ostrow School of Dentistry, University of Southern California, 1540 Alcazar Street, CHP-155, Los Angeles, CA 90033, USA</p>
<p><b>Notes</b></p>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	<p>Quote: "Participants were randomized 1:1 to one of four study groups."</p> <p>Quote: "The randomization list was prepared in advance by a bio-statistician, and allocation was conducted by the Clinical Investigation Support Office at the University of Southern California (USC) Norris Comprehensive Cancer Center."</p> <p>Judgement Comment: No specific information on how the allocation sequence was generated, but presume that the sequence generation was random. Assuming the ransomisation was done in a computer program as it was done by a biostatistician.</p>
Allocation concealment (selection bias)	Low risk	<p>Quote: "The randomization list was prepared in advance by a bio- statistician, and allocation was conducted by the Clinical Investigation Support Office at the University of Southern California (USC) Norris Comprehensive Cancer Center."</p> <p>Judgement Comment: Central allocation.</p>
Blinding of participants and personnel (performance bias)	High risk	<p>Quote: "Trial participants and investigators were not blinded to group allocation."</p> <p>Judgement Comment: No blinding.</p>



Blinding of outcome assessment (detection bias)	High risk	Quote: "Trial participants and investigators were not blinded to group allocation." Judgement Comment: No blinding.
Incomplete outcome data (attrition bias)	Low risk	Judgement Comment: Per protocol analyses, balanced numbers of dropouts between groups 3/16 (exercise) vs 2/19 (control), reasons stated.
Selective reporting (reporting bias)	Low risk	Judgement Comment: Protocol available both at clinical trials NCT01909440 and as a published protocol, outcome data were reported for all outcomes of interests specified in the published protocol. In register, and the protocol it is stated that ITT would be performed. This is not done, but it is only a pilot study.
Other bias	Low risk	Quote: "The authors declare that they have no competing interests." Judgement Comment: The study is at pilot study with 37 participants randomised. At clinical trials the actual enrolment is 43 participants.

**Focht 2018**

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial</p> <p><b>Study grouping:</b> Parallel group</p>
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 69.4 (9.0)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 28.5 (9.05)</li> <li>● Number of participants on ADT (%): 16 (100)</li> <li>● Time on ADT in months, mean (SD): 32.18 (27.28)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 64.5 (8.6)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 31.5 (6.23)</li> <li>● Number of participants on ADT (%): 16 (100)</li> <li>● Time on ADT in months, mean (SD): 15.31 (19.39)</li> </ul> <p><b>Included criteria:</b> (a) histologically defined diagnosis of prostate cancer based on pathology reports and staging studies; (b) currently undergoing androgen-deprivation therapy with a planned course of at least 3 months of continuous therapy; (c) sedentary activity pattern with less than 60 min of structured exercise participation per week during the past 6 months, consistent with recent lifestyle intervention trial's classification of inactivity; (d) free of poorly controlled medical conditions that precluded safe participation in an exercise program, such as uncontrolled coronary artery disease, hypertension, peripheral vascular disease, cerebral ischemia, congestive heart failure, chronic obstructive pulmonary disease, insulin-dependent diabetes, psychiatric disease, renal failure, liver failure, other active cancers, or anemia; (e) consent to participate from the treating oncologist and primary care physician; (f) willingness to accept randomization and undergo the testing and intervention procedures.</p> <p><b>Excluded criteria:</b> Not applicable.</p>
<b>Interventions</b>	<p><b>Intervention Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> The EX+D intervention involved a 12-week, multicomponent approach designed to facilitate exercise and dietary behavior change and promote adherence, independent of study staff, to these changes in lifestyle behavior. The exercise component of the EX+D intervention integrated a combination of supervised resistance and aerobic exercise performed twice per week. All supervised exercise sessions lasted 1 hr in duration. The exercise prescription was tailored to each individual's baseline functional abilities and exercise tolerance/capacity. Consequently,</li> </ul>

	<p>resistance exercise load, volume, and volume-load and aerobic exercise duration and intensity were guided by each participant's exercise tolerance and gradually increased across the intervention to progress toward optimal, targeted prescription ranges. Additionally, given that a primary goal of the intervention was to offset androgen deprivation-induced declines in muscle mass and strength, resistance exercise was the focal aspect of center-based training sessions. The progressive resistance exercise stimulus involved performing three sets at each individual's 8-12 repetition maximum (8RM-12RM) and a rating of perceived exertion (1-10) ranging from 3 (Moderately Hard) to 6 (Hard) for nine different exercises (leg extension, leg curl, chest press, latissimus dorsi pull-down, overhead press, triceps extension, bicep curl, calf raises, and abdominal crunch). To implement the resistance training principles of progression and overload, when participants were able to successfully complete two additional repetitions on two consecutive sets of an exercise, the resistance was increased by 5% for upper body exercises and 10% for lower body exercises. A 1-2 min rest interval was maintained between each set, and all sets were performed in a symptom-limited manner. The aerobic exercise stimulus consists of 10-20 min of exercise performed at a rating of perceived exertion (1-10) ranging from 3 (fairly light) to 4 (moderately hard) on the participant's choice of a treadmill, stationary cycle, or elliptical trainer. Participants were also encouraged to gradually increase independent, home-based exercise participation and purposeful activity and decrease sedentary time to progress toward accruing a volume of physical activity consistent with national guidelines for health (i.e., 150 min of physical activity per week and 10,000 steps per day).</p> <ul style="list-style-type: none"> <li>● <i>Dose</i>: 60 min , twice weekly.</li> <li>● <i>Duration</i>: 12 weeks</li> <li>● <i>Time on ADT in months, mean (SD)</i>: 32.18 (27.28)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <i>Description</i>: Men randomized to the SC control arm received usual prostate cancer treatment and standard disease management education, as well as additional educational literature describing the American Institute of Cancer Research dietary and physical activity guidelines and education</li> <li>● <i>Dose</i>: Not applicable</li> <li>● <i>Duration</i>: 12 weeks</li> <li>● <i>Time on ADT in months, mean (SD)</i>: 15.31 (19.39)</li> </ul>
--	--

<p><b>Outcomes</b></p>	<p>Livskvalitete (quality of life)</p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Not reported</li> </ul> <p><i>Fysisk funktion (physical function), 400 meter gangtest, mean change (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: 400 meter gangtest</li> <li>● <b>Unit of measure</b>: Seconds</li> <li>● <b>Direction</b>: Higher is better</li> <li>● <b>Data value</b>: Change from baseline</li> </ul> <p><i>Muskelstyrke (muscle strength), Leg extension, mean change (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: Leg extension</li> <li>● <b>Unit of measure</b>: Kg</li> <li>● <b>Direction</b>: Higher is better</li> <li>● <b>Data value</b>: change from baseline</li> </ul>
------------------------	--

	<p>Vo2 max (Vo2 peak)</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p>Depression (depression)</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p>Hjertekarsygdom (cardiovascular diseases)</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p>Diabetes (diabetes)</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p>Frakturer (fractures) antal personer med</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, Frakturer ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer der får fraktur</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p>Træningsrelaterede skader (Exercise related injuries) antal personer med</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, træningsrelaterede skader ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer med</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p>Frafald (dropouts) antal personer</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, frafald ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer der falder fra</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> This study is supported by National Cancer Institute (R03 CA16296901).</p> <p><b>Country:</b> USA</p> <p><b>Authors name:</b> Brian C. Focht</p> <p><b>Institution:</b> Department of Human Sciences, Exercise and Behavioral Medicine Laboratory, Kinesiology, The Ohio State University</p>

	<p><b>Email:</b> focht.10@osu.edu  <b>Address:</b> Department of Human Sciences, Exercise and Behavioral Medicine Laboratory, The Ohio State University, 305 Annie and John Glenn Ave, Columbus, OH 43210, USA</p>
<b>Notes</b>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Eligible participants were randomly assigned with equal probability to each of the two treatment arms using a 1:1 ratio following the completion of the baseline screening visit. The computer-generated randomization allocation sequence was sequentially numbered and sealed in opaque envelopes."
Allocation concealment (selection bias)	Low risk	Quote: "The computer-generated randomization allocation sequence was sequentially numbered and sealed in opaque envelopes. The randomization allocation sequence was also concealed from study staff responsible for conducting the baseline assessments."
Blinding of participants and personnel (performance bias)	High risk	Judgement Comment: No information on blinding of personnel and participants, blinding not feasible.
Blinding of outcome assessment (detection bias)	Low risk	Quote: "Assessments of all study outcomes were obtained at baseline, 2-month, and 3-month follow-up visits by trained study personnel who were blinded to participants' treatment assignment." Judgement Comment: Low risk for objective outcomes, no subjective outcomes of interest were reported.
Incomplete outcome data (attrition bias)	Low risk	Quote: "ANCOVA analyses were conducted using the intent-to-treat principle to account for missing data with the last observation carried forward (LOCF) approach, used to impute change across time to be zero." Judgement Comment: 11/16 in the usual care group dropped out vs 2/16 in the exercise group. Reasons for dropout stated. Intention to treat analyses performed with last observation carried forward for missing data.
Selective reporting (reporting bias)	High risk	Judgement Comment: Many outcomes in trial registry is not reported in study, but may be reported in other publications. Protocol available at <a href="http://clinicaltrials.gov">clinicaltrials.gov</a> . (NCT02050906) Change in global and disease-specific QOL assessed using the Satisfaction with Life Scale, the Short Form (SF)-36, and the Functional Assessment of Cancer Treatment-Prostate (FACT-P) were stated in the protocol, but not reported in the publication.
Other bias	Low risk	The study appears to be free of other sources of bias.

Galvao 2010

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial  <b>Study grouping:</b> Parallel group</p>
<b>Participants</b>	<p><b>Baseline Characteristics</b>                  Træning</p> <ul style="list-style-type: none"> <li>● Age in years - Mean (sd): 69,5 (7,3)</li> <li>● Height - cm: 171,1 (6,1)</li> <li>● Weight - kg: 80,7 (10,3)</li> </ul>

	<ul style="list-style-type: none"> <li>● BMI - kg/m<sup>2</sup>: 27,4 (3,2)</li> <li>● Number of participants on ADT (%): 29 (100)</li> <li>● Time on ADT in months, mean (SD): 18.2 (38.5)</li> </ul> <p>Kontrol (vanlig behandling)</p> <ul style="list-style-type: none"> <li>● Age in years - Mean(sd): 70,1 (7,3)</li> <li>● Height - cm: 172,0 (7,7)</li> <li>● Weight - kg: 83,2 (14,4)</li> <li>● BMI - kg/m<sup>2</sup>: 28,0 (3,8)</li> <li>● Number of participants on ADT (%): 28 (100)</li> <li>● Time on ADT in months, mean (SD): 10.1 (26.8)</li> </ul> <p><b>Included criteria:</b> Inclusion criteria included histologically documented prostate cancer, mini-mum prior exposure to AST longer than 2 months, without PSA evidence of disease activity, and anticipated to remain hypogonadal for the subsequent 6 months.</p> <p><b>Excluded criteria:</b> Exclusion criteria included bone metastatic disease, musculoskeletal, cardiovascular, or neurological disorders that could inhibit them from exercising, inability to walk 400 meters or undertake upper and lower limb exercise, and resistance training in the previous 3 months.</p> <p><b>Pretreatment:</b> There were no significant differences between groups at baseline.</p>
<p><b>Interventions</b></p>	<p><b>Intervention Characteristics</b></p> <p>Træning</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> Participants undertook combined progressive resistance and aerobic training twice a week for 12 weeks. The resistance exercises included the chest press, seated row, shoulder press, triceps extension, leg press, leg extension and leg curl, with abdominal crunches also performed. Sessions commenced and concluded with general flexibility exercises</li> <li>● <b>Intensity:</b> The resistance exercise program was designed to progress from 12- to 6 repetition maximum (RM) for two to four sets per exercise. The aerobic component of the training program included 15 to 20 minutes of cardio vascular exercises (cycling and walking/jogging) at 65% to 80% maximum heart rate and perceived exertion at 11 to 13(6 to 20 point, Borg scale</li> <li>● <b>weekly training sessions:</b> 2</li> </ul> <p>Kontrol (vanlig behandling)</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> Usual care. Control participants could undergo the training after the assessment period had been completed.</li> <li>● <b>Intensity:</b> Not applicable</li> <li>● <b>weekly training sessions:</b> Not applicable</li> </ul>
<p><b>Outcomes</b></p>	<p><i>Livskvalitet, Helbredsrelateret</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> SF-36, Physical health composite and mental health composite</li> <li>● <b>Range:</b> 0-100</li> <li>● <b>Unit of measure:</b> points</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p>Fysisk funktion</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> </ul>

- **Reporting:** Fully reported
- **Scale:** Repeated chair raise, 5 repetitions
- **Unit of measure:** Seconds
- **Direction:** Lower is better
- **Data value:** Endpoint

#### *Hjerte-kr sygdom*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

#### *Depression*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

#### *Diabetes*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

#### *Iltoptagelse (Vo2)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

#### *Muskelstyrke*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** Leg press 1RM
- **Unit of measure:** Kg
- **Direction:** Higher is better
- **Data value:** Endpoint

#### *Fraktur*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Fully reported
- **Unit of measure:** Numbers
- **Direction:** Lower is better
- **Data value:** Endpoint

#### *Bivirkninger, træningsrelaterede*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Fully reported
- **Unit of measure:** Numbers
- **Direction:** Lower is better
- **Data value:** Endpoint

Frafald, alle årsager

	<ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Unit of measure:</b> Numbers</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> Supported by the Cancer Council of Western Australia</p> <p><b>Country:</b> Australia</p> <p><b>Setting:</b> Sir Charles Gairdner Hospital (Perth, Western Australia)</p> <p><b>Authors name:</b> Daniel A. Galvão</p> <p><b>Institution:</b> School of Exercise, Biomedical and Health Sciences, Edith Cowan University</p> <p><b>Email:</b> d.galvao@ecu.edu.au</p> <p><b>Address:</b> 100 Joondalup Dr, Joondalup, Western Australia 6027, Australia;</p>
<b>Notes</b>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "participants were randomly assigned to the two arms: exercise (EX) or usual care controls (CO) in a ratio of 1:1 using a computer random assignment program"
Allocation concealment (selection bias)	Low risk	Quote: "The allocation sequence was concealed from the project coordinator and exercise physiologist involved in assigning participants to groups"
Blinding of participants and personnel (performance bias)	High risk	No information of blinding of participants and health care professionals. Blinding not feasible.
Blinding of outcome assessment (detection bias)	High risk	No information of blinding of outcome assessors. High risk for self reported outcomes (subjective outcomes).
Incomplete outcome data (attrition bias)	Low risk	Intention to treat analyses
Selective reporting (reporting bias)	Low risk	Protocol available ACTRN 126070000263493. Reports on all the outcomes stated in the protocol
Other bias	Low risk	The study appears to be free of other sources of bias

Galvao 2018

<p><b>Methods</b></p>	<p><b>Study design:</b> Randomized controlled trial  <b>Study grouping:</b> Parallel group</p>
<p><b>Participants</b></p>	<p><b>Baseline Characteristics</b>  Intervention</p> <ul style="list-style-type: none"> <li>● <i>Age in years, mean (SD): 69.7 (7.6)</i></li> <li>● <i>BMI, Kg/m<sup>2</sup>, mean (SD): 28.9 (4.1)</i></li> <li>● <i>Time since diagnosis in months, median (IQR): 20.5 (4.3-57.8)</i></li> <li>● <i>Number of participants on ADT (%): 27 (96.4)</i></li> <li>● <i>Time on ADT in months, median (IQR): 2.0 (1.0-6.3)</i></li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <i>Age in years, mean (SD): 70.4 (9.3)</i></li> <li>● <i>BMI, Kg/m<sup>2</sup>, mean (SD): 28.5 (4.0)</i></li> <li>● <i>Time since diagnosis in months, median (IQR): 39.0 (8.0-77.0)</i></li> <li>● <i>Number of participants on ADT (%): 27 (93.1)</i></li> <li>● <i>Time on ADT in months, median (IQR): 4.0 (1.0-9.0)</i></li> </ul> <p><b>Included criteria:</b> Inclusion criteria included established bone metastases according to their most recent bone scan, and this included at any time point of their bone metastatic disease (e.g., at onset of bone metastatic diagnosis or at any time point thereafter), no acute illness, and no significant bone pain as assessed by their clinician.  <b>Excluded criteria:</b> Exclusion criteria included the presence of any musculoskeletal, cardiovascular, or neurological disorders that could inhibit patients from exercising, and if patients had undertaken structured and supervised aerobic and/or resistance training two or more times per week within the past 3 months.</p>
<p><b>Interventions</b></p>	<p><b>Intervention Characteristics</b>  Intervention</p> <ul style="list-style-type: none"> <li>● <i>Description:</i> The M3EP comprised resistance, aerobic, and flexibility exercises undertaken three times per week in a university exercise clinic supervised by an exercise physiologist. In brief, the exercise prescription was based on location/extent of bone metastases to avoid specific loading of the sites (Table 1), with exercise sessions lasting 60 min. The resistance exercise component targeted the major trunk and upper and lower body muscle groups, which we have used in previous studies, at a moderate intensity ranging from 10- to 12-repetition maximum (RM);e.g., maximal weight that can be lifted 10–12 times) for three sets per exercise. Exercises were performed at a set cadence of 2 s for both eccentric and concentric phases, minimizing peak forces transmitted to the skeleton. To ensure progression, resistance was increased by 5%–10% for the next set/training session when the RM values were exceeded during a set. The aerobic exercise component included 20–30 min of cardiovascular exercise using various modes such as walking on a treadmill, cycling, or rowing on a stationary ergometer on the basis of disease extent with a target intensity of 60%–85% estimated maximal heart rate. The flexibility component involved static stretching, 2–4 repetitions for 30–60 s per stretch for all major joints considered important for maintaining function. Each session commenced with a 10-min warm-up comprising low-level aerobic activities such as treadmill walking and stationary cycling as determined by bone metastases site, as well as stretching, and concluded with a 5-min cool-down period of stretching activities. All participants will be asked to maintain customary physical activity and dietary patterns over the intervention period (apart from the programmed exercise).</li> <li>● <i>Dose:</i> 60 mins 3 times per week</li> <li>● <i>Duration:</i> 3 months</li> <li>● <i>Time on ADT in months, median (IQR): 2.0 (1.0-6.3)</i></li> </ul>



	<p>Control 1</p> <ul style="list-style-type: none"> <li>● <i>Description</i>: Usual care. All participants will be asked to maintain customary physical activity and dietary patterns over the intervention period</li> <li>● <i>Dose</i>: Not applicable</li> <li>● <i>Duration</i>: 3 months</li> <li>● <i>Time on ADT in months, median (IQR)</i>: 4.0 (1.0-9.0)</li> </ul>
<p><b>Outcomes</b></p>	<p><i>General livskvalitet (quality of life), SF 36, physical component, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: SF 36, physical component</li> <li>● <b>Range</b>: 0-100</li> <li>● <b>Unit of measure</b>: Points</li> <li>● <b>Direction</b>: Higher is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul> <p><i>Fysisk funktion (physical function), 400 meter gangtest, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: 400 meter gangtest</li> <li>● <b>Unit of measure</b>: Seconds</li> <li>● <b>Direction</b>: Higher is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul> <p><i>Fysisk funktion (physical function), timed up and go, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: Timed up and go</li> <li>● <b>Unit of measure</b>: Seconds</li> <li>● <b>Direction</b>: Lower is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul> <p><i>Fysisk funktion (physical function), 6 meters gangtest, fast, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: 6 meters gangtest, fast</li> <li>● <b>Unit of measure</b>: Seconds</li> <li>● <b>Direction</b>: Lower is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul> <p><i>Fysisk funktion (physical function), 6 meters gangtest, usual, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: 6 meters gangtest, usual</li> </ul>

- **Unit of measure:** Seconds
- **Direction:** Lower is better
- **Data value:** Endpoint

*Muskelstyrke (muscle strength), Leg extension, mean final (SD)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** Leg extension
- **Unit of measure:** Kg
- **Direction:** Higher is better
- **Data value:** Endpoint

*Vo2 max (Vo2 peak)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

*Depression (depression)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Hjertekarsygdom (cardiovascular diseases)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Diabetes (diabetes)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Frakturer (fractures) antal personer med*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Fully reported
- **Scale:** Dichotomous, frakturer ja/nej
- **Unit of measure:** Antal personer der får fraktur
- **Direction:** Lower is better
- **Data value:** Endpoint

*Træningsrelaterede skader (Exercise related injuries) antal personer med*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Fully reported
- **Scale:** Dichotomous, træningsrelaterede skader ja/nej
- **Unit of measure:** Antal personer med
- **Direction:** Lower is better
- **Data value:** Endpoint

*Frafald (dropouts) antal personer*

	<ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, fra/fald ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer der falder fra</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> Movember New Directions Development Award obtained through Prostate Cancer Foundation of Australia's Research Program</p> <p><b>Country:</b> Australia</p> <p><b>Authors name:</b> Daniel A. Galvao</p> <p><b>Institution:</b> Exercise Medicine Research Institute, Edith Cowan University</p> <p><b>Email:</b> d.galvao@ecu.edu.au.</p> <p><b>Address:</b> Exercise Medicine Research Institute, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA 6027, Australia</p>
<b>Notes</b>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "After the baseline assessment, patients were randomly assigned to exercise (EX) or usual care controls (CON) in a ratio of 1/1 using a computer random assignment program subject to maintaining approximate balance regarding stratification for current chemotherapy."
Allocation concealment (selection bias)	Low risk	Quote: "The allocation sequence was concealed from the project coordinator and exercise physiologist involved in assigning patients to groups."
Blinding of participants and personnel (performance bias)	High risk	Judgement Comment: No information on blinding of personnel and participants, blinding not feasible.
Blinding of outcome assessment (detection bias)	High risk	Judgement Comment: Quote from Galvao 2011 (protocol): "The exercise physiologists and other researchers conducting the study measures will be blinded to at given participant's group allocation". Primary outcome is based on self-assessment and blinding not feasible.
Incomplete outcome data (attrition bias)	Low risk	Judgement Comment: 5/28 dropped out in the exercise group vs 3/29 in the usual care group. reason stated. Low attrition rates in both groups and not related to intervention (intervention = 5/28, control 3/29).
Selective reporting (reporting bias)	Low risk	Judgement Comment: Protocol available at <a href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611001158954">https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12611001158954</a> and published protocol is also available. Outcome data were reported for all outcomes of interests specified in the protocols.
Other bias	Low risk	The study appears to be free of other sources of bias

Harrison 2018

<p><b>Methods</b></p>	<p><b>Study design:</b> Randomized controlled trial  <b>Study grouping:</b> Parallel group</p>
<p><b>Participants</b></p>	<p><b>Baseline Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 65.66 (8.11)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 64.37 (8.31)</li> </ul> <p><b>Included criteria:</b> a) Male age <math>\geq</math> 18 years; b) Histologically-confirmed adenocarcinoma of the prostate; c) Completion of appropriate prior treatment with local therapy (i.e., prostatectomy, radiation therapy or equivalent), per NCCN Guidelines; d) Detectable PSA, defined as PSA <math>\geq</math>0.01 ng/ml; e) Appropriate for treatment with ADT in the opinion of the treating physician.; f) Serum total testosterone <math>\geq</math>150 ng/dL (5.2 nmol/L); g) ECOG performance status of <math>\leq</math> 1 (Appendix A) h) Planned treatment with castration therapy (GnRH agonist/antagonist) for <math>\geq</math>8 months. i) Must not have any of the following absolute contraindications to cardiopulmonary exercise testing and/or aerobic training as determined by the attending oncologist: (Absolute Contraindications, Acute myocardial Infarction (within 3-5 days of any planned study procedures), Unstable angina, Uncontrolled arrhythmia causing symptoms or hemodynamic compromise, Active endocarditis, Acute myocarditis or pericarditis, Symptomatic severe aortic stenosis, Uncontrolled heart failure, Acute (within 3 months) pulmonary embolus or pulmonary infarction, Thrombosis of lower extremities, Suspected dissecting aneurysm, Uncontrolled asthma, Pulmonary edema, Room air desaturation at rest <math>&lt;</math>85%, Respiratory failure Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis), Mental impairment leading to inability to cooperate.) j) Able to swallow enzalutamide and comply with study requirements; k) Must be able to complete an acceptable cardiopulmonary exercise test (CPET) at baseline (see Section 9), defined as at least one of the following: (Achieving a plateau in oxygen consumption concurrent with an increase in power output; Respiratory exchange ratio <math>\geq</math> 1.1 (RER); Volitional exhaustion with a rating of perceived exertion <math>\geq</math> 17 (RPE)) l) Must be able to complete an acceptable muscular strength test (assessed using calculated one-repetition maximum (1-RM)) at baseline (see Section 9), in the opinion of the fitness specialist, exercise physiologist, or trained designee administering the test.m) Life expectancy of <math>\geq</math> 12 months.n) Must use a condom if having sex with a pregnant woman. o) Male subject and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration. Two acceptable methods of birth control thus include the following: Condom (barrier method of contraception); AND One of the following is required:Established use of oral, or injected or implanted hormonal method of contraception by the female partner; Placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female partner; Additional barrier method: Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the female partner; Tubal ligation in the female partner; Vasectomy or other procedure resulting in infertility (e.g., bilateral orchiectomy), for more than 6 monthsp) Subjects must have normal organ and marrow function as defined below: absolute neutrophil count <math>&gt;</math>1,500/<math>\mu</math>L, platelets <math>&gt;</math>100,000/<math>\mu</math>L, total bilirubin <math>&lt;</math>2.5 X institutional upper limit of normal,AST(SGOT)/ALT(SGPT) <math>&lt;</math>2.5 X institutional upper limit of normal,Creatinine <math>\leq</math> 2.0 OR creatinine clearance <math>&gt;</math>30 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.</p> <p><b>Excluded criteria:</b> a) Definite evidence of metastatic prostate cancer, in the opinion of the treating physician. Pelvic and retroperitoneal lymph nodes <math>&lt;</math> 2.0 cm in short axis are allowed. b) Subjects who have had treatments with GnRH agonists/antagonists and/or anti-androgens within 1 year of randomization. c) Use of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA values (e.g., saw palmetto) or systemic corticosteroids for prostate cancer within 4 weeks of day 29 visit (start of Enzalutamide and ADT). d) Subjects who have had radiotherapy within 12 weeks prior to entering the study or those who have not recovered from adverse events due to agents or therapies administered for treatment of prostate cancer more than 4 weeks earlier (except urinary, rectal, and sexual side effects related to prostatectomy or radiotherapy are</p>

	<p>permitted) e) Subjects who have had any surgical procedure (i.e. TURP, etc.) within 4 weeks prior to entering the study. f) Subjects who are receiving any other investigational agents. g) Significant cardiovascular disease, including: Symptomatic left ventricular dysfunction or known baseline left ventricular ejection fraction (LVEF) by multigated acquisition scan (MUGA) or echocardiogram (ECHO) of &lt; lower limit of institutional normal (LLN). "Symptomatic" is defined as New York Heart Association (NYHA) Class II or greater. Note: MUGA and ECHCO do NOT need to be measured to establish eligibility for this study. Uncontrolled hypertension (in the opinion of the treating provider). Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug. History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) within 12 months of first dose of study drug. Uncontrolled cardiac arrhythmias. Coronary or peripheral artery bypass graft within 6 months of first dose of study drug. History of CVA, TIA, or rest claudication within 6 months of first dose of study drug. h) Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements (in the opinion of the treating provider). i) Subjects with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation), prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs the ability to swallow and retain enzalutamide are excluded. j) History of another invasive cancer within 5 years of randomization with the exceptions of (a) non-melanoma skin cancers and (b) American Joint Committee on Cancer (AJCC) Stage 0 or 1 cancers that have a remote probability of recurrence, in the opinion of the treating physician, in consultation with the principal investigator. k) Known or suspected brain metastasis or leptomeningeal disease. l) History of seizure or any condition that may predispose to seizure (e.g., prior cortical stroke, significant brain trauma) at any time in the past. Also, history of loss of consciousness or transient ischemic attack within 12 months of the Day 1 visit.</p>
<p><b>Interventions</b></p>	<p><b>Intervention Characteristics</b> Intervention</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> The ENZ+ADT+Exercise arm will receive treatment with enzalutamide plus androgen deprivation therapy along with supervised exercise training. Exercise began 4 weeks prior to starting ADT p ENZ and consisted of 48 supervised exercise sessions delivered 3x/week between 55-80% of exercise capacity (VO2peak) for aerobic training and 60-85% of one repetition maximum (1-RM) for resistance training</li> <li>● <b>Dose:</b> 3 times/week</li> <li>● <b>Duration:</b> 16 weeks</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> The usual care arm will receive treatment with enzalutamide with androgen deprivation therapy, with no supervised exercise training.</li> <li>● <b>Dose:</b></li> <li>● <b>Duration:</b> 16 weeks</li> </ul>
<p><b>Outcomes</b></p>	<p><b>Diagnosespecifik livskvalitet (disease specific quality of life), Functional Assessment of Cancer Therapy Prostate (Fact P), mean change (SD)</b></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Partially reported</li> <li>● <b>Scale:</b> Functional Assessment of Cancer Therapy Prostate</li> <li>● <b>Range:</b> 0-156</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Change from baseline</li> </ul> <p><b>Fysisk funktion (physical function), rejse/sætte sig test, antal sekunder på 5 gentagelser mean change (SD)</b></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> </ul>

- **Scale:** rejse/sætte sig test
- **Unit of measure:** seconds
- **Direction:** Lower is better
- **Data value:** Change from baseline

*Fysisk funktion (physical function), 6 minutters gangtest, mean change (SD)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** 6 minutters gangtest
- **Unit of measure:** Meters
- **Direction:** Higher is better
- **Data value:** Change from baseline

*Muskelstyrke, leg press, mean change (SD)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** leg press
- **Unit of measure:** Kg
- **Direction:** Higher is better
- **Data value:** Change from baseline

*Vo2 max (Vo2 peak) mean change (SD)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** VO2 max
- **Unit of measure:** ml/Kg/min
- **Direction:** Higher is better
- **Data value:** Change from baseline

*Depression (depression)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Hjertekarsygdom (cardiovascular diseases)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Diabetes (diabetes)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Frakturer (fractures) antal personer med*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Fully reported
- **Scale:** Dichotomous, frakturer ja/nej

	<ul style="list-style-type: none"> <li>● <b>Unit of measure:</b> Antal personer der får fraktur</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Træningsrelaterede skader (Exercise related injuries) antal personer med</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, træningsrelaterede skader ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer med</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Frafald (dropouts) antal personer</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, frafald ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer der falder fra</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> Pheizer (Medivation), Astellas  <b>Authors name:</b> Michael Harrison  <b>Institution:</b> Duke University  <b>Email:</b> michael.harrison@duke.edu</p>
<b>Notes</b>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Judgement Comment: Once the subject has been registered, completed screening, and found to eligible post-baseline testing, the study coordinator at Duke will request the subject's random assignment to one of the two treatment arms from the Medidata RAVE database.
Allocation concealment (selection bias)	Low risk	Judgement Comment: The site will then be notified by the RAVE database to which arm the subject has been assigned.
Blinding of participants and personnel (performance bias)	High risk	Judgement Comment: Information from clinical neithersubjects nor study personnel will be blinded to treatment assignment. trials.gov: Masking: open label
Blinding of outcome assessment (detection bias)	High risk	Judgement Comment: Information from clinicaltrials.gov: Masking: open label. Critical outcome is self-reported
Incomplete outcome data (attrition bias)	Low risk	Judgement Comment: No dropouts. Outcome data are missing for few participants for some outcomes. No attrition in either groups

Selective reporting (reporting bias)	Low risk	Judgement Comment: Protocol and results available at clinicaltrials.gov. Outcome data were reported for all outcomes specified at clinicaltrials.gov.
Other bias	Unclear risk	Only an abstract is available. The study was originally designed to recruit 56 subjects but was halted early due to funding issues.

**Hojan 2017**

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial</p> <p><b>Study grouping:</b> Parallel group</p>
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 65.7 (6.2)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 26.42 (2.8)</li> <li>● Number of participants on ADT (%): 36 (100)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 67.9 (4.9)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 29.25 (3.7)</li> <li>● Number of participants on ADT (%): 36 (100)</li> </ul> <p>Overall</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 66.23 (4.94)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 28.69 (3.4)</li> <li>● Number of participants on ADT (%): 36 (100)</li> </ul> <p><b>Included criteria:</b> 1. Aged between 18 and 75 years; 2. Scheduled ADT (LH-analogue 10.8 mg every 3 months) planned to continue for a total period of 36 months (3 to 5 months prior to RT, during and after completion); 3. RT received a total dose of 76 Gy in 38 fractions (in the first phase of therapy, the pelvic lymph nodes along with the prostate gland and seminal vesicles were subjected to a dose of 46 Gy at 2 Gy fractions and in the second phase of therapy the irradiated volume was limited to prostate gland plus seminal vesicles to a total dose of 76 Gy); 4. Good general condition (Eastern Cooperative Oncology Group - ECOG- performance status 0-1).</p> <p><b>Excluded criteria:</b> 1. Distant metastases and/or disease progression resulting in RT or the introduction of chemotherapy; 2. Insufficiently controlled arterial hypertension or cardiac diseases resulting in circulation failure (above Stage II Heart Failure according to the New York Heart Association); 3. Insufficiently controlled metabolic diseases, endocrinological, rheumatic, and absorption disorders; 4. Other tumours; 5. Preexisting bone metastases at high risk for fracture; or with a psychiatric illness or dementia or organic brain disease.</p>
<b>Interventions</b>	<p><b>Intervention Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> All exercise training sessions in the exercise group consisted of 5 exercise sessions/wk for 8 weeks (during RT—between assessments I and II), and 3 d/wk for the next 10 months. The physical activities were performed either individually (strength training performed with the assistance of a physiotherapist) or in groups (exercises on treadmills or cycle ergometers, supervised by a therapist) and took place at a rehabilitation department. During RT, optional progressive exercise training included brisk walking, running indoors or on a treadmill, various cycling activities (30 min), and 25-minute resistance exercises (2 sets of 8 repetitions of 5 different exercises: bicep curl, triceps extension, leg extension, leg curl, and abdominal crunch) at 70% to 75% of their estimated one-repetition maximum. All activities lasted approximately 65 to 70</li> </ul>



	<p>minutes. The workout consisted of a 5-minute warm-up and 55 minutes of physical activity, followed by a 5-minute relaxation period. The physical activity was moderate, with a maximal heart rate of 65% to 70% (220-age). After RT, the exercise group performed a very similar exercise program 3 times/wk (ie, 1 day of exercise and 1 day of rest), but 1.5 h/d in our department. Exercise sessions consisted of 5 minutes of light warm-up and stretching, 40 minutes of middle-impact aerobics, 35 minutes of resistance training, and a 10-minute cool-down including relaxation. The prescribed aerobic intensity was 70% to 80% of heart rate reserve.</p> <ul style="list-style-type: none"> <li>● <b>Dose:</b> 5 exercise sessions/wk for 8 weeks (during RT—between assessments I and II), and 3 d/wk for the next 10 months. 65-75 min per session</li> <li>● <b>Duration:</b> 12 months</li> <li>● <b>Time on ADT in months, mean (SD):</b></li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> Patients randomized to the control group received usual care and physical activity according to recommendations. Clinicians provided medical clearance prior to the patients' involvement in the study. Patients in this group were given standard physical activity recommendations and were instructed via printed materials to perform 30 minutes of moderate physical activity 5 d/wk (150 min/wk). Patients randomized to this group were instructed not to begin any formal physical activities and perform usual daily activity at home</li> <li>● <b>Dose:</b></li> <li>● <b>Duration:</b> 12 months</li> </ul>
<p><b>Outcomes</b></p>	<p><b>Diagnosespecifik livskvalitet (disease specific quality of life), Functional Assessment of Cancer Therapy General (Fact G), mean final (SD)</b></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Functional Assessment of Cancer Therapy General</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><b>Diagnosespecifik livskvalitet (disease specific quality of life), EORTC QLQ-C30, subscale global health status, mean final (SD)</b></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> EORTC QLQ-C30, subscale global health status</li> <li>● <b>Range:</b> 0-100</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><b>Diagnosespecifik livskvalitet (disease specific quality of life), EORTC QLQ-C30, subscale, physical function, mean final (SD)</b></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> EORTC QLQ-C30, subscale, physical function</li> <li>● <b>Range:</b> 0-100</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>

*Fysisk funktion, 6 minutters gangtest, mean final (SD)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** 6 minutters gangtest
- **Unit of measure:** meters
- **Direction:** Higher is better
- **Data value:** Endpoint

*Muskelstyrke (Muscle strength)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

*Vo2 max (Vo2 peak)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

*Depression (depression)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Hjertekarsygdom (cardiovascular diseases)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Diabetes (diabetes)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Frakturer (fractures) antal personer med*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Fully reported
- **Scale:** Dichotomous, frakturer ja/nej
- **Unit of measure:** Antal personer der får fraktur
- **Direction:** Lower is better
- **Data value:** Endpoint

*Træningsrelaterede skader (Exercise related injuries) antal personer med*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Fully reported
- **Scale:** Dichotomous, træningsrelaterede skader ja/nej
- **Unit of measure:** Antal personer med
- **Direction:** Lower is better
- **Data value:** Endpoint

*Frafald (dropouts) antal personer*

	<ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, fra/fald ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer der falder fra</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> Greater Poland Cancer Centre (Poland)  <b>Country:</b> Poland  <b>Authors name:</b> Katarzyna Hojan  <b>Institution:</b> Department of Rehabilitation, Greater Poland Cancer Centre  <b>Email:</b> khojan@op.p  <b>Address:</b> Oddział Rehabilitacji, Wielkopolskie Centrum Onkologii, ul. Garbary 15, 61-866 Poznań, Poland,</p>
<b>Notes</b>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "For allocating the participants, a computer-generated list of random numbers was used. Patients were randomly assigned to one of the study groups (exercise group vs usual-care [control] group) following simple randomization procedures."
Allocation concealment (selection bias)	Low risk	Quote: "Concealed randomization was conducted using sequentially numbered opaque envelopes containing group assignments provided to participants following the baseline assessment."
Blinding of participants and personnel (performance bias)	High risk	Quote: "This study was not fully blinded; however, group allocation was concealed from the patients and the physiatrist until after the completion of the baseline assessments. A clinical research coordinator obtained patient consent, collected all the self-reported assessments, and explained the exercise program to participants. Laboratory assistants, study statistician, and data managers remained blinded at all times." Judgement Comment: Blinding of personnel and participants not feasible do to the nature of the interventions
Blinding of outcome assessment (detection bias)	High risk	Quote: "This study was not fully blinded; however, group allocation was concealed from the patients and the physiatrist until after the completion of the baseline assessments. A clinical research coordinator obtained patient consent, collected all the self-reported assessments, and explained the exercise program to participants. Laboratory assistants, study statistician, and data managers remained blinded at all times." recurrence. 10, 11 It has been" Judgement Comment: High risk for self-reported outcomes (quality of life, critical outcome)Low risk for objective outcomes (walking test, fractures)
Incomplete outcome data (attrition bias)	Unclear risk	Judgement Comment: No real intention to treat analysis, excludes participants with cancer progression during the period of radiation therapy. 5/36 dropped out in the usual care group, 1/36 in the exercise group. Low attrition in both groups (intervention 1/36, control 3/36). ITT analyses were performed for missing data but not drop-outs

Selective reporting (reporting bias)	Low risk	Judgement Comment: Protocol available at <a href="http://www.isrctn.com/ISRCTN80765858">http://www.isrctn.com/ISRCTN80765858</a> . Retrospectively registered. Outcomes were not specified in details in the protocol. Primary outcome measure 1. Efficacy of physical exercises (data from questionnaires) 2. Blood inflammation markers. 3. Assessment of functional capacity, fatigue and QoL during PCa treatment. Outcome data were reported for all outcomes specified in the methods section (Hojan 2016)
Other bias	Low risk	The study appears to be free of other sources of bias.

**Najvera 2020**

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial</p> <p><b>Study grouping:</b> Parallel group</p>
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 71.4 (5.4)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 28.4 (3.1)</li> <li>● Number of participants on ADT (%): 24 (100)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 72.5 (4.2)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 27.7 (3.4)</li> <li>● Number of participants on ADT (%): 26 (100)</li> </ul> <p>Overall</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 72.0 (4.8)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 28.0 (3.3)</li> <li>● Number of participants on ADT (%): 50 (100)</li> </ul> <p><b>Included criteria:</b> Histologically confirmed prostate cancer, aged 50–80 years, beginning LHRH agonist treatment with or without radiotherapy, anticipated to remain on ADT for ≥6 months, be classified as 0 or 1 according to the WHO performance status, and not achieving 150 min/week of moderate intensity physical activity during the last 6 months</p> <p><b>Excluded criteria:</b> Metastatic bone disease, previously treated with ADT, involvement in any other clinical trial, prior CV event or heart failure, chronic obstructive pulmonary disease, and an absolute contraindication to exercise testing or training.</p>
<b>Interventions</b>	<p><b>Intervention Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> Patients completed two supervised exercise sessions per week for 12 weeks upon initiating ADT. Each session lasted 60 min and included aerobic interval exercise on a cycle ergometer (Monark 824E; Varberg, Sweden) followed by resistance training. The aerobic exercise component involved a 5 min warm-up at light resistance (50 W) followed by 6 x 5 min bouts at an intensity of 11–15 on the 6–20 Borg Rating of Perceived Exertion (RPE) Scale, corresponding to 55–85% of the age-predicted maximum heart rate (220 – age). Patients maintained a cadence of 50 rev/min and each 5 min bout was separated by 2.5 min of active recovery at light resistance (50 W). As patients became accustomed to the exercise, they were encouraged to progress towards the upper threshold of intensity by adding further load to the cycle ergometer flywheel. The resistance training component included six exercises that targeted the major muscle groups (dumbbell squat, modified press-up, dumbbell bent-over row, dumbbell bicep curl, short arc quad, wall squat). Patients performed 2–4 sets of 10 repetitions at 1–15 RPE, which is a valid</li> </ul>

	<p>method of monitoring resistance training intensity in this population. Each exercise was separated by 30 s of passive rest. Resistance training stimuli were progressed weekly by increasing the external load and/or increasing the number of sets. In addition to the supervised exercise sessions, patients were advised to increase their habitual physical activity levels and were encouraged to engage in 30 min of self directed structured exercise or physical activity on 3 days each week (e.g., brisk walking, cycling, home-based resistance training). After the withdrawal of supervision (i.e., after the 3-month supervised intervention had finished), patients were instructed to continue exercising and to maintain self-directed levels of physical activity.</p> <ul style="list-style-type: none"> <li>● <b>Dose:</b> 60 min, twice weekly</li> <li>● <b>Duration:</b> 12 weeks</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> Standard care</li> <li>● <b>Dose:</b> Not applicable</li> <li>● <b>Duration:</b> 12 weeks</li> </ul>
<p><b>Outcomes</b></p>	<p><b>Diagnosespecifik livskvalitet (disease specific quality of life), Functional Assessment of Cancer Therapy Prostate (Fact P), mean final (SD)</b></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Functional Assessment of Cancer Therapy Prostate</li> <li>● <b>Range:</b> 0-156</li> <li>● <b>Unit of measure:</b> Points</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><b>Fysisk funktion (physical function)</b></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><b>Muskelstyrke, håndgrebsstyrke, mean final (SD)</b></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Håndgrebsstyrke</li> <li>● <b>Unit of measure:</b> Kg</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><b>Vo2 max (Vo2 peak) mean final (SD)</b></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Vo2 max</li> <li>● <b>Unit of measure:</b> ml/Kg/min</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><b>Depression (depression)</b></p>

	<ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Hjertekarsygdom (cardiovascular disease)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Diabetes (diabetes)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Frakturer (fractures) antal personer med</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, frakturer ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer der får fraktur</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Træningsrelaterede skader (Exercise related injuries) antal personer med</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, træningsrelaterede skader ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer med</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Fraald (dropouts) antal personer</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, fraald ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer der falder fraa</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> No information</p> <p><b>Country:</b> UK</p> <p><b>Setting:</b> Urology multi-disciplinary team at the Norfolk and Norwich University Hospitals NHS Foundation Trust, UK</p> <p><b>Authors name:</b> Wilphard Ndjavera</p> <p><b>Institution:</b> Department of Urology, Norfolk and Norwich University Hospital, Norwich, UK</p>
<b>Notes</b>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "standard care plus exercise group using a randomisation sequence created by an independent researcher (nQuery, Statistical Solutions Ltd, Boston, MA, USA)." Quote: "prospective, randomised controlled trial (RCT). <b>After baseline testing, patients were randomly allocated 1:1 to a standard care</b> control group or a standard".
Allocation concealment (selection bias)	Low risk	Quote: "Treatment allocation was concealed from the research team until after baseline measurements were collected. Outcome assessors and data analysts".
Blinding of participants and personnel (performance bias)	High risk	Judgement Comment: No information on blinding of personnel and participants, blinding not feasible.
Blinding of outcome assessment (detection bias)	High risk	Quote: "Outcome assessors and data analysts were blind to treatment allocation. Outcomes were assessed at baseline." Judgement Comment: Low risk for objective outcomes (muscle strength and V02 peak) High risk for subjective putcomes (quality of life) Critical outcome.
Incomplete outcome data (attrition bias)	Low risk	Quote: "To comply with intention-to-treat and increase precision of the estimates, missing data at 3-months (n = 8) and 6-months (n = 13) were multiply imputed using predictive mean matching with 20 iterations." Judgement Comment: 2/24 dropped out in the exercise group vs 6/26 in the control group. reasons stated. Reasons not presumed to be related to the outcome.
Selective reporting (reporting bias)	Low risk	Judgement Comment: Outcomes reported matches those in protocolNCT03776045
Other bias	Low risk	The study appears to be free of other sources of bias

Newton 2020/Taaffe 2019

<b>Methods</b>	<b>Study design:</b> Randomized controlled trial <b>Study grouping:</b> Parallel group
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 69.0 (6.3)</li> <li>● BMI, Kg/m2, mean (SD): 27.5 (4.4)</li> <li>● Number of participants on ADT (%): 54 (100)</li> <li>● Days since first ADT injection, mean (SD): 6.4 (2.1)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 67.5 (7.7)</li> <li>● BMI, Kg/m2, mean (SD): 28.3 (3.9)</li> <li>● Number of participants on ADT (%): 50 (100)</li> <li>● Days since first ADT injection, mean (SD): 5.7 (1.9)</li> </ul>

	<p><b>Included criteria:</b> Commencing ADT and intending to remain on it for at least the next 6 months; No structured aerobic or resistance exercise in the past 3 months; Able to walk 400 m.</p> <p><b>Excluded criteria:</b> Prior ADT; Established metastatic disease; Established osteoporosis; Medications known to affect bone metabolism; Acute illness or any musculoskeletal, cardiovascular or neurological disorder that could inhibit or put them at risk from exercising as determined by their physician.</p>
<p><b>Interventions</b></p>	<p><b>Intervention Characteristics</b> Intervention</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> Sessions were conducted in small groups of 6–10 participants supervised by accredited exercise physiologists. The sessions were 60 min in duration and consisted of a combination of impact loading, aerobic and resistance exercise. The frequency of aerobic and resistance exercise was alternated weekly such that two aerobic/impact loading and one resistance/impact loading session were performed in 1 week and two resistance/impact loading and one aerobic/impact loading session were performed in the subsequent week. Briefly, the impact-loading component consisted of a series of bounding (over soft hurdles), hopping, skipping, leaping, and drop jumping activities that resulted in peak ground reaction forces of 3.4–5.2 times body weight, with the volume and intensity progressive in nature. For the first 8 weeks, two rotations were performed of skipping (30 s), bounding (15 cm hurdles), and jumping (10 times), with jumping replaced in weeks 5–8 by drop jumping (15 cm, 10 times). For the second 8 weeks, three rotations were performed of bounding (15–30 cm hurdles), drop jumping (15–20 cm, 10 times), and skipping (30 s), with skipping replaced in weeks 13–16 by hopping/leaping (10 times). There after, four rotations of hopping/leaping (10 times), bounding (30 cm hurdles), and drop jumping (20 cm, 10 times) were performed. Resistance training consisted of upper and lower body exercises for the main muscle groups and included the leg press, leg extension, leg curl, chest press, seated row, lat pulldown, and biceps curl. Intensity was set at 6–12 repetition maximum (RM; the maximal weight lifted 6–12 times) using 2–4 sets/exercise. The aerobic-based component consisted of various modes and included walking/jogging on a treadmill and cycling or rowing on a stationary ergometer at an intensity of 60–85% estimated maximum heart rate for 25–40 min, with heart rate monitored using heart rate watches (Polar Electro Oy, Finland). All sessions commenced with a warm-up comprising low-level aerobic activities and concluded with a cool down of stretching activities. In addition to clinic-based exercise, the men were encouraged to undertake twice weekly home-based training consisting of aerobic activities such as walking or cycling and a modified version of the impact-loading programme consisting of hopping, leaping, and drop jumping.</li> <li>● <b>Dose:</b> 60 min, three times per week</li> <li>● <b>Duration:</b> 6 months + 6 months. We use data for the end of the first 6 months of supervised exercise.</li> <li>● <b>Days since first ADT injection, mean (SD):</b> 6.4 (2.1)</li> </ul> <p><b>Control</b></p> <ul style="list-style-type: none"> <li>● <b>Description:</b> Delayed exercise. Usual care for the first 6 months followed by 6 months of supervised exercise (same program as the intervention group, but first after 6 months).</li> <li>● <b>Dose:</b> Not applicable ( for the 6 months of usual care).</li> <li>● <b>Duration:</b> 6 months of usual care followed by 6 months supervised exercise. We use data for the end of the 6 months of usual care.</li> <li>● <b>Days since first ADT injection, mean (SD):</b> 5.7 (1.9)</li> </ul>
<p><b>Outcomes</b></p>	<p><i>Livskvalitet (quality of life)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Fysisk funktion (physical function), rejse/sætte sig test, antal sekunder på 5 gentagelser, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> rejse/sætte sig test</li> </ul>



- **Unit of measure:** Seconds
- **Direction:** Lower is better
- **Data value:** Endpoint

*Fysisk funktion, 400 meter gangtest, mean final (SD)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** 400 meter gangtest
- **Unit of measure:** Seconds
- **Direction:** Higher is better
- **Data value:** Endpoint

*Fysisk funktion, 6 meters gangtest, fast, mean final (SD)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** 6 meters gangtest, fast
- **Unit of measure:** Seconds
- **Direction:** Lower is better
- **Data value:** Endpoint

*Fysisk funktion, 6 meters gangtest, usual, mean final (SD)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** 6 meters gangtest, usual
- **Unit of measure:** Seconds
- **Direction:** Lower is better
- **Data value:** Endpoint

*Muskelstyrke, Benpres, mean final (SD)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Fully reported
- **Scale:** Benpres
- **Unit of measure:** Kg
- **Direction:** Higher is better
- **Data value:** Endpoint

*Vo2 max (Vo2 peak)*

- **Outcome type:** Continuous Outcome
- **Reporting:** Not reported

*Depression (depression)*

- **Outcome type:** Dichotomous Outcome
- **Reporting:** Not reported

*Hjertekar sygdom (cardiovascular disease)*

	<ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Diabetes (diabetes)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Frakturer (fractures) antal personer med</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, frakturer ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer der får fraktur</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Træningsrelaterede skader (Exercise related injuries) antal personer med</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, træningsrelaterede skader ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer med</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Fraald (dropouts) antal personer</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, fraald ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer der falder fra</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> This study was funded by Cancer Australia, Prostate Cancer Foundation of Australia and Beyond Blue (NHMRC#1029901). DAG is funded by a Cancer Council Western Australia Research Fellowship. SKC is supported by an Australian Research Council Professorial Future Fellowship</p> <p><b>Country:</b> Australia</p> <p><b>Authors name:</b> Robert U. Newton</p>
<b>Notes</b>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Following familiarisation and baseline assessments, 104 men were randomly assigned using a computer random assignment program to either immediate exercise (IMEX) or delayed exercise (DEL), and stratified according to age ( $\leq 70$ and $>70$ years) and smoking status (yes/no)."
Allocation concealment (selection bias)	Low risk	Quote: "This was a single-blinded randomised controlled trial (RCT; investigators and testing personnel blinded to group allocation)" Judgement Comment: Investigators were blinded for group allocation.
Blinding of participants and personnel (performance bias)	High risk	Quote: "This was a single-blinded randomised controlled trial (RCT; investigators and testing personnel blinded to group allocation)" Judgement Comment: No blinding of personnel and participants Not possible to blind participants or personnel.
Blinding of outcome assessment (detection bias)	Low risk	Quote: "investigators and testing personnel blinded to group allocation)" Judgement Comment: Low risk for objective outcomes, no subjective outcomes.
Incomplete outcome data (attrition bias)	Low risk	Quote: "Intention-to-treat was used for analyses of primary and secondary endpoints using maximum-likelihood imputation of missing values (expectation maximisation). Freidman's ANOVA with Bonferroni-adjusted Wilcoxon" Judgement Comment: 6/54 dropped out in the exercise group vs 13/50 in the delayed training group (control group). Reasons stated. Intention to treat analyses were performed.
Selective reporting (reporting bias)	High risk	Judgement Comment: Our critical outcomes quality of life were included as an outcome in registry but not reported in study, but might be included in other studies. <a href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=347946">https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=347946</a> Quote: Quality of Life: quality of life will be assessed using the SF-36, EORTC QLQ-C30, EORTC QLQ-PR25 and EPIC-26 questionnaires.
Other bias	Low risk	The study appears to be free of other sources of bias.

### Nilsen 2015

<b>Methods</b>	<b>Study design:</b> Randomized controlled trial <b>Study grouping:</b> Parallel group
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>Træning</p> <ul style="list-style-type: none"> <li>● Age - Mean(sd): 66 (6.6)</li> <li>● Number of participants on ADT (%): 28 (100)</li> <li>● Time on ADT in months, mean (SD): 9.0 (1.6)</li> </ul> <p>Kontrol (vanlig behandling)</p> <ul style="list-style-type: none"> <li>● Age - Mean(sd): 66 (5)</li> <li>● Number of participants on ADT (%): 30 (100)</li> <li>● Time on ADT in months, mean (SD): 9.0 (1.8)</li> </ul> <p><b>Included criteria:</b> Prostate cancer patients with an intermediate- or high risk profile, which was determined based on serum levels of prostate specific antigen and the histology and extent of the primary tumour. All patients had been referred to high-dose radiotherapy, which started 2-6 months after the initiation of neo-adjuvant ADT, followed by adjuvant ADT, which was continued for 9-36 months.</p>

	<p>Other criteria were: age ≤75 years, ability tounderstand Norwegian, residence less than 1 hour by car from the training facility.  <b>Excluded criteria:</b> Regular strength training (≥1 session per week), use of osteoporosis medication, and/or medical conditions that could complicate participation.</p> <p><b>Intervention Characteristics</b></p> <p>Træning</p> <ul style="list-style-type: none"> <li>● <i>Description:</i> The patients performed three sessions pre week for 16 weeks. Each session included nine exercises (smith machine half squat, leg press, smith machine standing calf raises, knee flexion, knee extension, chest press, seated row, seated shoulder press and biceps curl)</li> <li>● <i>Intensity:</i> After two weeks of familiarisation, including low resistance corresponding to 40-50% of 1RM in two sets of 10 repetitions, the training programme followed a daily undulating periodisation model, with a linear progression model, with a linear progression in training volume through the intervention period: 1-3 sets of 10RM on Mondays, and 2-3 sets of 6RM on Fridays. A submaximal session was carried out on Wednesdays with 10 reps with 80-90% of 10RM in 2-3 sets.</li> <li>● <i>weekly training sessions:</i> 3</li> </ul> <p>Kontrol (vanlig behandling)</p> <ul style="list-style-type: none"> <li>● <i>Description:</i> Usual care for 16 weeks.</li> <li>● <i>Intensity:</i> Not applicable</li> <li>● <i>weekly training sessions:</i> Not applicable</li> </ul>
<p><b>Outcomes</b></p>	<p><i>Livskvalitet, Helbredsrelateret</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> EORTC QLQ-C30 Global Health Status and quality of life subscale</li> <li>● <b>Range:</b> 0-100</li> <li>● <b>Unit of measure:</b> points</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p>Fysisk funktion</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Repeated chair raise</li> <li>● <b>Unit of measure:</b> Repetitions in 30 seconds</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Hjerte-kar sygdom</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Depression</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul>

	<p><i>Diabetes</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>lftoptagelse (Vo2)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p>Muskelstyrke</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Leg press 1RM</li> <li>● <b>Unit of measure:</b> Kg</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Fraktur</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Unit of measure:</b> Numbers</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p>Bivirkninger, træningsrelaterede</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Unit of measure:</b> Numbers</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p>Frafald, alle årsager</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Unit of measure:</b> Numbers</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<p><b>Identification</b></p>	<p><b>Sponsorship source:</b> Supported by the Norwegian Foundation of Health and rehabilitation and the Norwegian Cancer Society. Co-funded by the regional Health Authority in Southern Norway. Additional funding by Eckbo's legacy, The Rdlum Hospital's legacy and Trivselsanlegget's legacy.</p> <p><b>Country:</b> norway</p> <p><b>Setting:</b> Two units at the Oslo University Hospital in Norway.</p> <p><b>Authors name:</b> Nilsen</p>
<p><b>Notes</b></p>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The allocation sequence was computer generated/generated.
Allocation concealment (selection bias)	Unclear risk	No information of allocation concealment.
Blinding of participants and personnel (performance bias)	High risk	No information of blinding of participants and health care professionals. Blinding not feasible.
Blinding of outcome assessment (detection bias)	High risk	No information of blinding of outcome assessors. High risk for self-reported outcomes (Quality of life).
Incomplete outcome data (attrition bias)	Low risk	Low number of dropouts, reasons stated.
Selective reporting (reporting bias)	Low risk	Trial registration: Clinicaltrials.gov identifier: NCT00658229. The study reports on all the outcomes of interests that were stated in the methods section.
Other bias	Low risk	The study appears to be free of other sources of bias

Segal 2003

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial</p> <p><b>Study grouping:</b> Parallel group</p>
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>Træning</p> <ul style="list-style-type: none"> <li>● Age in years - Mean(sd): 68.2 (7.9)</li> <li>● Højde - cm: Not reported</li> <li>● Vægt - kg: 88.0 (12.6)</li> <li>● BMI - kg/m<sup>2</sup>: 29.0 (3.5)</li> <li>● Time since diagnosis in months, mean (SD): 32.2 (36.7)</li> <li>● Number of participants on ADT (%): 82 (100)</li> <li>● Time on ADT in months, mean (SD): 12.3 (18.7)</li> </ul> <p>Kontrol (vanlig behandling)</p> <ul style="list-style-type: none"> <li>● Age in years - Mean(sd): 67.7 (7.5)</li> <li>● Højde - cm: Not reported</li> <li>● Vægt - kg: 86.7 (13.0)</li> <li>● BMI - kg/m<sup>2</sup>: 28.5 (3.7)</li> <li>● Time since diagnosis in months, mean (SD): 25.1 (42.5)</li> <li>● Number of participants on ADT (%): 73 (100)</li> <li>● Time on ADT in months, mean (SD): 13.2 (21.9)</li> </ul>

	<p><b>Included criteria:</b> They were eligible if they had histologically documented prostate cancer, were scheduled to receive androgen deprivation therapy for at least 3 months after recruitment, and if the treating oncologist provided consent. It was not necessary for patients to be newly diagnosed with prostate cancer.</p> <p><b>Excluded criteria:</b> Men were excluded if they had severe cardiac disease (New York Heart Association class III or greater), uncontrolled hypertension (blood pressure 160/95 mmHg), uncontrolled pain, unstable bone lesions, or residence more than 1 hour from the study center.</p> <p><b>Pretreatment:</b> The groups were balanced in terms of age, body weight, body mass index, time from diagnosis, time receiving hormone therapy, cancer stage grouping, treatment intent, prior physical activity level, and experience with resistance exercise</p>
<p><b>Interventions</b></p>	<p><b>Intervention Characteristics</b> Træning</p> <ul style="list-style-type: none"> <li>● <i>Description:</i> Resistance exercise consisted of a 12-week program of nine strength-training exercises carried out under supervision, at 60% to 70% of one-repetition maximum (1-RM; the maximum amount of weight that can be lifted once), estimated from the standard loadtest. Patients were free to complete their program at any time during the fitness centers' hours of operation. No attempt was made to place patients in groups to exercise, although in some cases more than one participant in the intervention group inadvertently showed up to exercise at the same time of day</li> <li>● <i>Intensity:</i> Two sets of eight to 12 repetitions of the following nine exercises were performed: leg extension, calf raises, leg curl, chest press, latissimus pull-down, overhead press, triceps extension, biceps curls, and modified curl-ups. Sixty percent of the participant's 1-RM was used as the starting resistance. Patients were instructed to increase the resistance by 5 lb when they were able to complete more than 12 repetitions.</li> <li>● <i>weekly training sessions:</i> three times per week</li> </ul> <p>Kontrol (vanlig behandling)</p> <ul style="list-style-type: none"> <li>● <i>Description:</i> Men in the control group were offered the identical exercise advice and guidance; however, it was not provided until after the 12-week waiting period.</li> <li>● <i>Intensity:</i> Not applicable</li> <li>● <i>weekly training sessions:</i> Not applicable</li> </ul>
<p><b>Outcomes</b></p>	<p><i>Livskvalitet, diagnose specifik</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> FACT-P</li> <li>● <b>Range:</b> 0-156</li> <li>● <b>Unit of measure:</b> points</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Change from baseline</li> </ul> <p>Fysisk funktion</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Hjerte-kar sygdom</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Depression</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> </ul>

	<ul style="list-style-type: none"> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>Diabetes</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p><i>lftoptagelse (Vo2)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p>Muskelstyrke</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Continuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Leg press repetition maximum</li> <li>● <b>Unit of measure:</b> Number of repetitions</li> <li>● <b>Direction:</b> Higher is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Fraktur</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p>Bivirkninger, træningsrelaterede</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Not reported</li> </ul> <p>Frafeld, alle årsager</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Unit of measure:</b> Numbers</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
	<p><b>Identification</b></p> <p><b>Sponsorship source:</b> Supported by the National Cancer Institute of Canada (NCIC) with funds from the Canadian Cancer Society (CCS; grant in aid of research no.009458). R.D.R. is supported by a New Investigator Award from the Heartand Stroke Foundation of Canada. K.S.C. is supported by an InvestigatorAward from the Canadian Institutes of Health Research and a Research Team Grant from the NCIC with funds from the CCS and the CCS/NCIC Sociobehavioral Cancer Research Network.</p> <p><b>Country:</b> Canada</p> <p><b>Setting:</b> The trial was coordinated at the Ottawa Regional Cancer Centre (Ottawa, Ontario, Canada). The other participating center was the Cross Cancer Institute in Edmonton (Alberta, Canada).</p> <p><b>Comments:</b> Not reported</p> <p><b>Authors name:</b> Roanne J. Segal</p> <p><b>Institution:</b> Department of Medical Oncology, Ottawa Regional Cancer Centre-General Site,</p> <p><b>Email:</b> email: Roanne.Segal@orcc.on.ca.</p>



<b>Address:</b> 503 Smyth Rd, Ottawa, Ontario K1H 1C4, Canada	
<b>Notes</b>	

**Risk of bias table**

<b>Bias</b>	<b>Authors' judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	Quote: "Using a table of random numbers"
Allocation concealment (selection bias)	Unclear risk	No information of allocation concealment.
Blinding of participants and personnel (performance bias)	High risk	No information of blinding of participants and health care professionals. Blinding not feasible.
Blinding of outcome assessment (detection bias)	High risk	No information of blinding of outcome assessors. Outcome measures were self-reported and blinding not feasible.
Incomplete outcome data (attrition bias)	Unclear risk	8 drop outs in the intervention group, 12 in the control group, no reasons stated
Selective reporting (reporting bias)	Low risk	No protocol available. Study reports on outcomes mentioned in article.
Other bias	Low risk	The study appears to be free of other sources of bias

**Segal 2009a**

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial  <b>Study grouping:</b> Parallel group</p>
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>Intervention 1</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 66.4 (7.6)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 28.1 (3.5)</li> <li>● Number of participants on ADT (%): 23 (57.5)</li> </ul> <p>Intervention 2</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 66.2 (6.8)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 28.9 (3.4)</li> <li>● Number of participants on ADT (%): 25 (62.5)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 65.3 (7.6)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 29.0 (4.2)</li> <li>● Number of participants on ADT (%): 26 (63.4)</li> </ul> <p>Overall</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 66.3 (7.0)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 28.6 (12.2)</li> <li>● Time since diagnosis in months, mean (SD):</li> </ul>

	<ul style="list-style-type: none"> <li>● <i>Number of participants on ADT (%)</i>: 74 (61.2)</li> </ul> <p><b>Included criteria:</b> Men were eligible to participate if they had histologically documented PCa, were scheduled to receive radiotherapy with or without ADT, and if the treating oncologist approved.</p> <p><b>Excluded criteria:</b> Men were excluded if they had severe cardiac disease (New York Heart Association functional class III or IV), uncontrolled hypertension, pain, psychiatric illness, or lived more than 1 hour away.</p>
<p><b>Interventions</b></p>	<p><b>Intervention Characteristics</b></p> <p>Intervention 1</p> <ul style="list-style-type: none"> <li>● <i>Description</i>: Resistance training participants exercised three times per week performing two sets of eight to 12 repetitions of 10 different exercises (leg extension, leg curl, seated chest fly, latissimus pulldown, overhead press, triceps extension, biceps curls, calf raises, low back extension, and modified curl-ups) at 60% to 70% of their estimated one-repetition maximum(1 RM).Resistance was increased by 5 lb when participants completed more than 12 repetitions.</li> <li>● <i>Dose</i>: 3 times per week. Exercise duration began at 15 minutes and increased by 5 minutes every 3 weeks until it reached 45 minutes. Exercise intensity was standardized using heart rate monitors.</li> <li>● <i>Duration</i>: 24 weeks</li> </ul> <p>Intervention 2</p> <ul style="list-style-type: none"> <li>● <i>Description</i>: Aerobic training participants exercised three times perweek on a cycle ergometer, treadmill, or elliptical trainer beginning at 50% to 60% of their predetermined peak oxygen consumption (VO2peak) for weeks 1 to 4 and progressing to 70% to 75% for weeks 5 to 24.</li> <li>● <i>Dose</i>: 3 times per week. Exercise duration began at 15 minutes and increased by 5 minutes every 3 weeks until it reached 45 minutes. Exercise intensity was standardized using heart rate monitors.</li> <li>● <i>Duration</i>: 24 weeks</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● <i>Description</i>: Usual care. Usual care participants were asked not to initiate exercise and were offered a program, post intervention assessments.</li> <li>● <i>Dose</i>: Not applicable</li> <li>● <i>Duration</i>: 24 weeks</li> </ul>
<p><b>Outcomes</b></p>	<p><i>Diagnosespecifik livskvalitet, (Disease specific quality of life), Functional Assessment of Cancer Therapy Prostate (Fact P) mean final, SD</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: Functional Assessment of Cancer Therapy Prostate</li> <li>● <b>Range</b>: 0-156</li> <li>● <b>Unit of measure</b>: Points</li> <li>● <b>Direction</b>: Higher is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul> <p><i>Diagnosespecifik livskvalitet, (diagnose specific quality of life), Functional Assessment of Cancer Therapy General (Fact G) mean final, SD</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: ContinuousOutcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: Functional Assessment of Cancer Therapy General</li> <li>● <b>Unit of measure</b>: Points</li> <li>● <b>Direction</b>: Higher is better</li> </ul>

- **Data value** : Endpoint
- Fysisk funktion (physical function)*
- **Outcome type** : Continuous Outcome
  - **Reporting** : Not reported
- Muskelstyrke (muscle strength) Benpres, mean final (SD)*
- **Outcome type** : Continuous Outcome
  - **Reporting** : Fully reported
  - **Scale** : benpres
  - **Unit of measure** : Kg
  - **Direction** : Higher is better
  - **Data value** : Endpoint
- Vo2 max (Vo2 peak) mean final (SD)*
- **Outcome type** : Continuous Outcome
  - **Reporting** : Fully reported
  - **Scale** : Vo2 max
  - **Unit of measure** : ml/Kg/min
  - **Direction** : Higher is better
  - **Data value** : Endpoint
- Depression (depression)*
- **Outcome type** : Dichotomous Outcome
  - **Reporting** : Not reported
- Hjertekarsygdom (cardiovascular disease)*
- **Outcome type** : Dichotomous Outcome
  - **Reporting** : Not reported
- Diabetes (diabetes)*
- **Outcome type** : Dichotomous Outcome
  - **Reporting** : Not reported
- Frakturer (fractures) antal personer med*
- **Outcome type** : Dichotomous Outcome
  - **Reporting** : Fully reported
  - **Scale** : Dichotomous, frakturer ja/nej
  - **Unit of measure** : Antal personer med fraktur
  - **Direction** : Lower is better
  - **Data value** : Endpoint
- Træningsrelaterede skader (exercise related injuries) antal personer med*
- **Outcome type** : Dichotomous Outcome
  - **Reporting** : Fully reported

	<ul style="list-style-type: none"> <li>● <b>Scale:</b> Dichotomous, træningsrelaterede skader ja/nej</li> <li>● <b>Unit of measure:</b> antal personer</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p><i>Frafald (dropouts) antal personer</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dichotomous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Scale:</b> Dichotomous, frafald ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> Supported by Grant No. 013232 from the Canadian Prostate Cancer Research Fund</p> <p><b>Country:</b> Canada</p> <p><b>Authors name:</b> Roanne J. Segal</p> <p><b>Institution:</b> University of Ottawa</p> <p><b>Email:</b> rsegal@ottawahospital.on.ca</p> <p><b>Address:</b> University of Ottawa, 501 Smyth Rd, Ottawa, Ontario, Canada K1H 8L6</p>
<b>Notes</b>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Central random assignment was used, with allocation concealment before assignment." Quote: "participants underwent random assignment). Participants were stratified by intended duration of ADT ( 16 weeks/ none v ADT 16 weeks) and randomly assigned to one of three groups: resistance training, aerobic training, or usual care using computer-generated numbers.Central random assignment was used." Judgement Comment: Presume the method was sufficient.
Allocation concealment (selection bias)	Low risk	Quote: "Central random assignment was used, with allocation concealment before assignment. To ensure blinding of the research coordinator, an exercise specialist handled the random assignments."
Blinding of participants and personnel (performance bias)	High risk	Judgement Comment: No information. Not possible to blind participants or personnel.
Blinding of outcome assessment (detection bias)	High risk	Judgement Comment: No information. High risk of bias for subjective outcomes (quality of life), since blinding of participants were not feasible.
Incomplete outcome data (attrition bias)	Unclear risk	Judgement Comment: 7/40 in the resistance exercise group dropped out, 3/40 in the aerobic exercise group and 1 in the usual care group. Reasons for dropouts were not stated. Intention to treat analyses were performed.

Selective reporting (reporting bias)	Low risk	Judgement Comment: No reference to a protocol, reports on all the outcomes stated in the methods section. One of our critical outcome of interest were not included in the trial (function).
Other bias	Low risk	The study appears to be free of other sources of bias

**Segal 2009b**

<b>Methods</b>	See Segal 2009a
<b>Participants</b>	
<b>Interventions</b>	
<b>Outcomes</b>	
<b>Identification</b>	
<b>Notes</b>	

**Risk of bias table**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Central random assignment was used, with allocation concealment before assignment." Quote: "participants underwent random assignment). Participants were stratified by intended duration of ADT ( 16 weeks/ none v ADT 16 weeks) and randomly assigned to one of three groups: resistance training, aerobic training, or usual care using computer-generated numbers.Central random assignment was used," Judgement Comment: Presume the method was sufficient.
Allocation concealment (selection bias)	Low risk	Quote: "Central random assignment was used, with allocation concealment before assignment. To ensure blinding of the research coordinator, an exercise specialist handled the random assignments."
Blinding of participants and personnel (performance bias)	High risk	Judgement Comment: No information. Not possible to blind participants or personnel.
Blinding of outcome assessment (detection bias)	High risk	Judgement Comment: No information. High risk of bias for subjective outcomes (quality of life), since blinding of participants were not feasible.
Incomplete outcome data (attrition bias)	Unclear risk	Judgement Comment: 7/40 in the resistance exercise group dropped out, 3/40 in the aerobic exercise group and 1 in the usual care group. Reasons for dropouts were not stated. Intention to treat analyses were performed.
Selective reporting (reporting bias)	Low risk	Judgement Comment: No reference to a protocol, reports on all the outcomes stated in the methods section. One of our critical outcome of interest were not included in the trial (function).
Other bias	Low risk	The study appears to be free of other sources of bias

[Taafe2017/Newton 2019/Wall2017a](#)

Methods	See Taafe2017/Newton2019/Wall2017b
Participants	
Interventions	
Outcomes	
Identification	
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "participants were stratified according to time on ADT (< 6 mo or ≥ 6 mo) and randomly allocated to: impact loading + resistance training (ILRT), aerobic + resistance training (ART), or to usual care/delayed exercise (DEL) by computer random assignment."
Allocation concealment (selection bias)	Low risk	Judgement Comment: Wall, 2017: The allocation sequence was concealed from the project coordinator and exercise physiologist involved in assigning participants to groups
Blinding of participants and personnel (performance bias)	High risk	Judgement Comment: No information on blinding of personnel and participants, blinding not feasible. Open (masking not used) <a href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83774">https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83774</a> .
Blinding of outcome assessment (detection bias)	High risk	Judgement Comment: From trial register: Open (masking not used) <a href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83774">https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83774</a>
Incomplete outcome data (attrition bias)	Low risk	Quote: "Intention to treat was utilised for all analyses using maximum likelihood imputation of missing values (expectation maximisation)." Judgement Comment: 15/58 dropped out in the resistance/impact group, 7/54 in the resistance/cardiovascular group and 15/51 in the usual care group (delayed exercise). Reasons stated. Intention to treat analyses.
Selective reporting (reporting bias)	High risk	Judgement Comment: Protocol available at <a href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83774&amp;showOriginal=true&amp;isReview=true">https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83774&amp;showOriginal=true&amp;isReview=true</a> . Retrospectively registered Our critical outcome quality of life were included in the protocol, but not reported in the publications. Since the trial were conducted between 2009 and 2012 we presume that the authors have had sufficient time to publish all results. from the protocol: Secondary outcome: Questionnaire (EORTC QLQ-C30), European Organization for Research and Treatment of Cancer ? Prostate Specific Module (EORTC QLQ-PR25), Medical Outcomes Study Short-Form 36 (SF-36), and The Brief Symptom Inventory-18 (BSI-18).
Other bias	Low risk	The study appears to be free of other sources of bias

Taaffe 2017/Newton 2019/Wall2017b

<p><b>Methods</b></p>	<p><b>Study design:</b> Randomized controlled trial  <b>Study grouping:</b> Parallel group</p>
<p><b>Participants</b></p>	<p><b>Baseline Characteristics</b></p> <p>Intervention 1</p> <ul style="list-style-type: none"> <li>● <i>Age in years, mean (SD):</i> 68.9 (9.1)</li> <li>● <i>BMI, Kg/m<sup>2</sup>, mean (SD):</i> 28.1 (3.5)</li> <li>● <i>Number of participants on ADT (%):</i> 57 (100)</li> <li>● <i>Time on ADT in months, mean (SD):</i> 4.2 (4.5)</li> </ul> <p>Intervention 2</p> <ul style="list-style-type: none"> <li>● <i>Age in years, mean (SD):</i> 69.0 (9.3)</li> <li>● <i>BMI, Kg/m<sup>2</sup>, mean (SD):</i> 28.0 (3.7)</li> <li>● <i>Number of participants on ADT (%):</i> 54 (100)</li> <li>● <i>Time on ADT in months, mean (SD):</i> 5.3 (7.6)</li> </ul> <p>Control 1</p> <ul style="list-style-type: none"> <li>● <i>Age in years, mean (SD):</i> 68.4 (9.1)</li> <li>● <i>BMI, Kg/m<sup>2</sup>, mean (SD):</i> 30.3 (4.8)</li> <li>● <i>Number of participants on ADT (%):</i> 48 (100)</li> <li>● <i>Time on ADT in months, mean (SD):</i> 3.7 (3.7)</li> </ul> <p><b>Included criteria:</b> Histologically documented PCa; Minimum exposure to ADT of 2 months; Without prostate-specific antigen (PSA) evidence of disease activity; Anticipated to receive ADT for the subsequent 12 months.  <b>Excluded criteria:</b> Bone metastatic disease; Musculoskeletal, cardiovascular, or neurological conditions that could inhibit them from exercising, inability to walk 400 m or undertake exercise; Structured resistance and aerobic training in the previous 3 months.</p>
<p><b>Interventions</b></p>	<p><b>Intervention Characteristics</b></p> <p>Intervention 1</p> <ul style="list-style-type: none"> <li>● <i>Description:</i> Impact loading + resistance training (ILRT): ILRT was undertaken twice weekly in University-affiliated exercise clinics for 12 mo. Sessions were supervised with up to 10 participants. The impact-loading component consisted of a series of bounding, skipping, drop jumping, hopping, and leaping activities that produced ground reaction forces of 3.4–5.2 times body weight, and was progressive in nature. Resistance training consisted of six principal exercises that targeted the major upper and lower body muscle groups: chest press, seated row, shoulder press, leg press, leg extension, and leg curl, with supplementary exercises. Patients performed two to four sets of each exercise at an intensity of 6–12 RM (maximal weight that can be lifted 6–12 times). In addition, the ILRT group undertook home training twice weekly that consisted of two to four rotations of skipping/hopping/leaping/drop jumping</li> <li>● <i>Dose:</i> Twice weekly</li> <li>● <i>Duration:</i> 12 months</li> <li>● <i>Time on ADT in months, mean (SD):</i> 4.2 (4.5)</li> </ul> <p>Intervention 2</p> <ul style="list-style-type: none"> <li>● <i>Description:</i> Aerobic + resistance training (ART): ART underwent supervised exercise in the clinic twice weekly for the initial 6 mo. The</li> </ul>

	<p>aerobic-based component consisted of 20–30 min of exercise at 60–75% of estimated maximal heart rate using various modes which included walking/jogging and cycling or rowing on stationary ergometers. Resistance exercise during the initial 6 mo was the same as that undertaken in the ILRT regimen. In addition, participants were encouraged to undertake home-based aerobic activity such as walking or cycling with the goal to accumulate 150 min/wk of aerobic activity. For the 2nd 6 mo, patients were provided with a home-based maintenance program similar to our previous report</p> <ul style="list-style-type: none"> <li>● <i>Dose</i>: Twice weekly</li> <li>● <i>Duration</i>: 12 months</li> <li>● <i>Time on ADT in months, mean (SD)</i>: 5.3 (7.6)</li> </ul> <p>Control 1</p> <ul style="list-style-type: none"> <li>● <i>Description</i>: Usual care/delayed exercise (DEL): DEL were provided with a printed booklet with information about exercise for the initial 6 mo (endpoint of interest for our comparison), followed by 6 mo of twice weekly supervised exercise on a cycle ergometer at an intensity of 70% maximal heart rate and flexibility exercises in the clinic</li> <li>● <i>Dose</i>:</li> <li>● <i>Duration</i>: 6 months (for our comparison of interest) + 6 months</li> <li>● <i>Time on ADT in months, mean (SD)</i>: 3.7 (3.7)</li> </ul>
<p><b>Outcomes</b></p>	<p><i>Livskvalitet (quality of life)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Not reported</li> </ul> <p><i>Fysisk funktion, 400 meter gangtest, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: 400 meter gangtest</li> <li>● <b>Unit of measure</b>: Seconds</li> <li>● <b>Direction</b>: Higher is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul> <p><i>Muskelstyrke (muscle strength), Leg press, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: Leg press</li> <li>● <b>Unit of measure</b>: Kg</li> <li>● <b>Direction</b>: Higher is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul> <p><i>Muskelstyrke (muscle strength), Leg extension, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: Leg extension</li> <li>● <b>Unit of measure</b>: Kg</li> <li>● <b>Direction</b>: Higher is better</li> </ul>



	<ul style="list-style-type: none"> <li>● <b>Data value</b> : Endpoint</li> </ul> <p><i>Vo2 max (Vo2 peak)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Not reported</li> </ul> <p><i>Depression (depression)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Dichotomous Outcome</li> <li>● <b>Reporting</b>: Not reported</li> </ul> <p><i>Hjertekarsygdom (cardiovascular disease)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Dichotomous Outcome</li> <li>● <b>Reporting</b>: Not reported</li> </ul> <p><i>Diabetes (diabetes)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Dichotomous Outcome</li> <li>● <b>Reporting</b>: Not reported</li> </ul> <p><i>Frakturer (fractures) antal personer med</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Dichotomous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: Dichotomous, frakturer ja/nej</li> <li>● <b>Unit of measure</b>: Antal personer der får fraktur</li> <li>● <b>Direction</b>: Lower is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul> <p><i>Træningsrelaterede skader (Exercise related injuries) antal personer med</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Dichotomous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: Dichotomous, træningsrelaterede skader ja/nej</li> <li>● <b>Unit of measure</b>: Antal personer med</li> <li>● <b>Direction</b>: Lower is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul> <p><i>Frafald (dropouts) antal personer</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Dichotomous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: Dichotomous, frafald ja/nej</li> <li>● <b>Unit of measure</b>: Antal personer der falder fra</li> <li>● <b>Direction</b>: Lower is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul>
--	--

<b>Identification</b>	<p><b>Sponsorship source:</b> National Health and Medical Research Council 534409, Prostate Cancer Foundation of Australia, Cancer Council of Western Australia, and Cancer Council of Queensland</p> <p><b>Country:</b> Australia</p> <p><b>Authors name:</b> Dennis R. Taaffe</p> <p><b>Institution:</b> Exercise Medicine Research Institute, School of Medical and Health Sciences, Edith Cowan University,</p> <p><b>Email:</b> d.taaffe@ecu.edu.au</p> <p><b>Address:</b> Exercise Medicine Research Institute, School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA 6027, Australia</p>
<b>Notes</b>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "participants were stratified according to time on ADT (< 6 mo or ≥ 6 mo) and randomly allocated to: impact loading + resistance training (ILRT), aerobic + resistance training (ART), or to usual care/delayed exercise (DEL) by computer random assignment."
Allocation concealment (selection bias)	Low risk	Judgement Comment: Walli, 2017: The allocation sequence was concealed from the project coordinator and exercise physiologist involved in assigning participants to groups
Blinding of participants and personnel (performance bias)	High risk	Judgement Comment: No information on blinding of personnel and participants, blinding not feasible. Open (masking not used) <a href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83774">https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83774</a> .
Blinding of outcome assessment (detection bias)	High risk	Judgement Comment: From trial register: Open (masking not used) <a href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83774">https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83774</a>
Incomplete outcome data (attrition bias)	Low risk	Quote: "Intention to treat was utilised for all analyses using maximum likelihood imputation of missing values (expectation maximisation)." Judgement Comment: 15/58 dropped out in the resistance/impact group, 7/54 in the resistance/cardiovascular group and 15/51 in the usual care group (delayed exercise). Reasons stated. Intention to treat analyses.
Selective reporting (reporting bias)	High risk	Judgement Comment: Protocol available at <a href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83774&amp;showOriginal=true&amp;isReview=true">https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83774&amp;showOriginal=true&amp;isReview=true</a> . Retrospectively registered Our critical outcome quality of life were included in the protocol, but not reported in the publications. Since the trial were conducted between 2009 and 2012 we presume that the authors have had sufficient time to publish all results. from the protocol: Secondary outcome: Questionnaire (EORTC QLQ-C30), European Organization for Research and Treatment of Cancer ? Prostate Specific Module (EORTC QLQ-PR25), Medical Outcomes Study Short-Form 36 (SF-36), and The Brief Symptom Inventory-18 (BSI-18).
Other bias	Low risk	The study appears to be free of other sources of bias

Uth 2014

<p><b>Methods</b></p>	<p><b>Study design:</b> Randomized controlled trial  <b>Study grouping:</b> Parallel group</p>
<p><b>Participants</b></p>	<p><b>Baseline Characteristics</b></p> <p>Træning</p> <ul style="list-style-type: none"> <li>● <i>Age in years - Mean (sd):</i> 67.1(7.1)</li> <li>● <i>Højde - cm:</i> 177.0(5.7)</li> <li>● <i>Vægt - kg:</i> 83.4 (11.6)</li> <li>● <i>BMI - kg/m<sup>2</sup>:</i> 26.6 (3.2)</li> <li>● Time since diagnosis in days, median (IQR): 453 (374-2077)</li> <li>● <i>Number of participants on ADT (%):</i> 29 (100)</li> <li>● Time on ADT in days, median (IQR):376 (285-833)</li> </ul> <p>Kontrol (vanlig behandling)</p> <ul style="list-style-type: none"> <li>● <i>Age in years - Mean(sd):</i> 66.5 (4.9)</li> <li>● <i>Højde - cm:</i> 180.8 (5.4)</li> <li>● <i>Vægt - kg:</i> 89.0 (11.9)</li> <li>● <i>BMI - kg/m<sup>2</sup>:</i> 27.6 (2.8)</li> <li>● Time since diagnosis in days, median (IQR): 671 (383-1359)</li> <li>● <i>Number of participants on ADT (%):</i> 28 (100)</li> <li>● Time on ADT in days, median (IQR): 560 (283-1049)</li> </ul> <p><b>Included criteria:</b> Patients presenting at Copenhagen Prostate Cancer Center, Copenhagen University Hospital, Rigshospitalet, or the Department of Urology, Frederiksberg Hospital, Denmark aged &lt; 76 years managed with ADT, i.e., LHRHa, or surgical castration, forat least 6 months were eligible.  <b>Excluded criteria:</b> Main criteria for exclusion were cardiovascular disorders, osteoporosis, and activity limiting pain from bone metastases.  <b>Pretreatment:</b> The groups were well balanced following randomization, although participants in CON were taller than participantsin FG (P = 0.01). stor forskel i muskel studrke og funktionelle test. Kontrolgruppen har højeste målinger. OBS: ADT time (days) 376 (285-833) 560 (283-1049) OBS: PSA level at diagnosis 18 (10-39) 28 (15-43)</p>
<p><b>Interventions</b></p>	<p><b>Intervention Characteristics</b></p> <p>Træning</p> <ul style="list-style-type: none"> <li>● <i>Description:</i> Participants in the FG performed football. During the first 4 weeks, the football training consisted of two weekly sessions, which started with 15 min of warm-up exercises (running, dribbling, passing, shooting, balance, and muscle strength exercises) followed by 2x15 min of 5-7 a-side small-sided games. In weeks5-8, the duration of each session increased to 3x15-min games after the warm-up, and in weeks 9-12, there were three weekly training sessions of the same duration.</li> <li>● <i>Intensity:</i> Not reported</li> <li>● <i>weekly training sessions:</i> 12 weeks, 2-3 times weekly</li> </ul> <p>Kontrol (vanlig behandling)</p> <ul style="list-style-type: none"> <li>● <i>Description:</i> Participants in CON were encouraged to maintain their baseline physical activity level and were offered 12 weeks football training after the assessment period had been completed.</li> <li>● <i>Intensity:</i> Not applicable</li> </ul>

	<p>● <i>weekly training sessions</i>: Not applicable</p> <p><b>Outcomes</b></p> <p><i>Livskvalitet</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Not reported</li> </ul> <p><i>Fysisk funktion</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: Repeated chair raise</li> <li>● <b>Unit of measure</b>: Repetitions in 30 seconds</li> <li>● <b>Direction</b>: Higher is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul> <p><i>Hjerte-kar sygdom</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Dichotomous Outcome</li> <li>● <b>Reporting</b>: Not reported</li> </ul> <p><i>Depression</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Not reported</li> </ul> <p><i>Diabetes</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Dichotomous Outcome</li> <li>● <b>Reporting</b>: Not reported</li> </ul> <p><i>Iltoptagelse (Vo2)</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Not reported</li> <li>● <b>Scale</b>: Vo2 max</li> <li>● <b>Unit of measure</b>: ml/Kg/min</li> <li>● <b>Direction</b>: Higher is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul> <p><i>Muskelstyrke</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Continuous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> <li>● <b>Scale</b>: Knee extensor 1RM</li> <li>● <b>Unit of measure</b>: Kg</li> <li>● <b>Direction</b>: Higher is better</li> <li>● <b>Data value</b>: Endpoint</li> </ul> <p><i>Fraktur</i></p> <ul style="list-style-type: none"> <li>● <b>Outcome type</b>: Dichotomous Outcome</li> <li>● <b>Reporting</b>: Fully reported</li> </ul>
--	--

	<ul style="list-style-type: none"> <li>● <b>Unit of measure:</b> Numbers</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p>Bivirkninger, træningsrelaterede</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Unit of measure:</b> Numbers</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul> <p>Fraifald, alle årsager</p> <ul style="list-style-type: none"> <li>● <b>Outcome type:</b> Dictomuous Outcome</li> <li>● <b>Reporting:</b> Fully reported</li> <li>● <b>Unit of measure:</b> Numbers</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> The study was supported by grants from TheCenter for Integrated Rehabilitation of Cancer patients (CIRE), acenter established and supported by The Danish Cancer Society and The Novo Nordisk Foundation. The project was also supported by TrygFonden, Preben &amp; Anna Simonsen Fonden and The Beckett Foundation.</p> <p><b>Country:</b> Denmark</p> <p><b>Setting:</b> The University Hospitals Centre for Health Research (UCSF),</p> <p><b>Comments:</b> NCT01711892</p> <p><b>Authors name:</b> Jacob Uth</p> <p><b>Institution:</b> The University Hospitals Centre for Health Research (UCSF), Copenhagen University Hospital Rigshospitalet</p> <p><b>Email:</b> ju@ucsf.dk</p> <p><b>Address:</b> Blegdamsvej 9, 2100 Copenhagen, Denmark</p>
<b>Notes</b>	

**Risk of bias table**

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information of how the allocation sequence was generated.
Allocation concealment (selection bias)	Unclear risk	No information of allocation concealment.
Blinding of participants and personnel (performance bias)	High risk	No information of blinding of participants and health care professionals. Blinding not feasible.

Blinding of outcome assessment (detection bias)	Unclear risk	No information of blinding of outcome assessors.
Incomplete outcome data (attrition bias)	Low risk	Low number of dropouts reasons stated
Selective reporting (reporting bias)	High risk	Protocol available at <a href="http://clinicaltrials.gov">clinicaltrials.gov</a> . Outcomes of interests stated in the protocol, but not reported (quality of life and HADS). Results from these outcomes are not found in other publications from the same trial. Uth 2016a, Uth 2016b
Other bias	Low risk	The study appears to be free of other sources of bias

**Winters Stone 2015**

<b>Methods</b>	<p><b>Study design:</b> Randomized controlled trial  <b>Study grouping:</b> Parallel group</p>	
<b>Participants</b>	<p><b>Baseline Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 69.9 (9.3)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 28.4 (4.1)</li> <li>● Time since diagnosis in months, mean (SD): 79.2 (58.9)</li> <li>● Number of participants on ADT (%): 29 (100 %)</li> <li>● Time on ADT in months, mean (SD): 39.0 (36.1)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● Age in years, mean (SD): 70.5 (7.8)</li> <li>● BMI, Kg/m<sup>2</sup>, mean (SD): 29.6 (4.8)</li> <li>● Time since diagnosis in months, mean (SD): 75.6 (56.0)</li> <li>● Number of participants on ADT (%): 22 (100%)</li> <li>● Time on ADT in months, mean (SD): 28.5 (29.2)</li> </ul> <p><b>Included criteria:</b> Participants with a confirmed diagnosis of prostate cancer, currently receiving ADT but no other cancer treatment, clear of bone metastases in the hip or spine, with bone mineral density T score <math>\geq -2.5</math>, with no antiresorptive medications, with no participation in resistance and/or impact training <math>\geq 2</math> times per week and <math>\geq 30</math> minutes per session, and with physician clearance to exercise.</p> <p><b>Excluded criteria:</b> Not Applicable.</p>	
<b>Interventions</b>	<p><b>Intervention Characteristics</b></p> <p>Intervention</p> <ul style="list-style-type: none"> <li>● <b>Description:</b> Participants in both groups were prescribed an exercise program of 2 supervised classes and 1 home-based session per week for 12 months. The POWIR program was based on our prior interventions in people without cancer and was aimed to increase musculoskeletal health and function in older adults through resistance plus impact training. Free weights were used to apply resistance and included dumbbells, barbells, and weighted vests (loaded as percentage bodyweight). Resistance exercises were all multijoint and emphasized movements common to activities of daily living, including wall-sits, squats, bent-knee dead lifts, multi directional lunges, 1-arm row, chest press, lateral raise, and push-ups. Impact exercise, consisting of 50 two-footed jumps, was included to mechanically load the skeleton for bone outcomes. For home exercise, resistance bands replaced free weights and body weight replaced weighted vests for upper-body exercises and lower-body exercises, respectively.</li> </ul>	

	<ul style="list-style-type: none"> <li>● Dose: 2 supervised classes and 1 home-based session per week</li> <li>● Duration: 12 months</li> <li>● Time on ADT in months, mean (SD): 39.0 (36.1)</li> </ul> <p>Control</p> <ul style="list-style-type: none"> <li>● Description: Participants in both groups were prescribed an exercise program of 2 supervised classes and 1 home-based session per week for 12 months. Participants in the control group performed a series of seated or lying whole-body stretching and relaxation exercises aimed to minimize weight-bearing forces and muscle activation. For home exercise, control participants followed a written guideline of stretches and relaxation used in class. A gentle exercise placebo group was used as a control rather than a usual care group to equalize attention, maximize retention, and minimize contamination.</li> <li>● Dose: 2 supervised classes and 1 home-based session per week</li> <li>● Duration: 12 months</li> <li>● Time on ADT in months, mean (SD): 28.5 (29.2)</li> </ul>
<p><b>Outcomes</b></p>	<p><i>Diagnosespecifik livskvalitet (disease specific quality of life), EORTC QLQ-C30, subscale, physical function, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● Outcome type: Continuous Outcome</li> <li>● Reporting: Fully reported</li> <li>● Scale: EORTC QLQ-C30, subscale, physical function</li> <li>● Range: 0-100</li> <li>● Unit of measure: Points</li> <li>● Direction: Higher is better</li> <li>● Data value: Endpoint</li> </ul> <p><i>Fysisk funktion (physical function), rejse/sætte sig test, antal sekunder på 5 gentagelser, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● Outcome type: Continuous Outcome</li> <li>● Reporting: Fully reported</li> <li>● Scale: seconds</li> <li>● Direction: Lower is better</li> <li>● Data value: Endpoint</li> </ul> <p><i>Fysisk funktion (physical function), 4 meters gangtest, fast, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● Outcome type: Continuous Outcome</li> <li>● Reporting: Fully reported</li> <li>● Scale: 4 meters gangtest, fast</li> <li>● Unit of measure: Seconds</li> <li>● Direction: Lower is better</li> <li>● Data value: Endpoint</li> </ul> <p><i>Fysisk funktion (physical function), 4 meters gangtest, usual, mean final (SD)</i></p> <ul style="list-style-type: none"> <li>● Outcome type: Continuous Outcome</li> <li>● Reporting: Fully reported</li> <li>● Scale: 4 meters gangtest, usual</li> <li>● Unit of measure: seconds</li> <li>● Direction: Lower is better</li> </ul>

- **Data value** : Endpoint

*Muskelstyrke (muscle strength), Leg press, mean final (SD)*

- **Outcome type** : Continuous Outcome
- **Reporting** : Fully reported
- **Scale** : Leg press
- **Unit of measure** : Kg
- **Direction** : Higher is better
- **Data value** : Endpoint

*Vo2 max (Vo2 peak)*

- **Outcome type** : Continuous Outcome
- **Reporting** : Not reported

*Depression (depression)*

- **Outcome type** : Dichotomous Outcome
- **Reporting** : Not reported

*Hjertekarsygdom (cardiovascular disease)*

- **Outcome type** : Dichotomous Outcome
- **Reporting** : Not reported

*Diabetes (diabetes)*

- **Outcome type** : Dichotomous Outcome
- **Reporting** : Not reported

*Frakturer (fractures) antal personer med*

- **Outcome type** : Dichotomous Outcome
- **Reporting** : Fully reported
- **Scale** : Dichotomous, frakturer ja/nej
- **Unit of measure** : Antal personer der får fraktur
- **Direction** : Lower is better
- **Data value** : Endpoint

*Træningsrelaterede skader (Exercise related injuries) antal personer med*

- **Outcome type** : Dichotomous Outcome
- **Reporting** : Fully reported
- **Scale** : Dichotomous, træningsrelaterede skader ja/nej
- **Unit of measure** : Antal personer med
- **Direction** : Lower is better
- **Data value** : Endpoint

*Frafald (dropouts) antal personer*

- **Outcome type** : Dichotomous Outcome
- **Reporting** : Fully reported



	<ul style="list-style-type: none"> <li>● <b>Scale:</b> Dichotomous, frafald ja/nej</li> <li>● <b>Unit of measure:</b> Antal personer der falder fra</li> <li>● <b>Direction:</b> Lower is better</li> <li>● <b>Data value:</b> Endpoint</li> </ul>
<b>Identification</b>	<p><b>Sponsorship source:</b> Supported by the Livestrong Foundation (formerly Lance Armstrong Foundation); and TheraBand, Inc, for providing elastic exercise bands for study participants.</p> <p><b>Country:</b> USA</p> <p><b>Authors name:</b> Kerri M. Winters-Stone</p> <p><b>Institution:</b> Knight Cancer Institute, Oregon Health &amp; Science University</p> <p><b>Email:</b> wintersk@ohsu.edu</p> <p><b>Address:</b> Oregon Health &amp; Science University, 3455 SW US Veteran's Hospital Rd, Mailcode: SN-ORD, Portland, OR 97239</p>
<b>Notes</b>	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Randomization was stratified by length of ADT use (>1 or ≤1y) and current aerobic activity (≥90 min/wk vs <90min/wk) and occurred after baseline testing." Judgement Comment: Assuming from the description it is done by computer
Allocation concealment (selection bias)	Unclear risk	Judgement Comment: No information on how the allocation sequence was concealed
Blinding of participants and personnel (performance bias)	High risk	Judgement Comment: Trial described as single blinded, testers were blinded, no information on blinding of personnel and participants, blinding not feasible.
Blinding of outcome assessment (detection bias)	Low risk	Quote: "Tests were administered by trained technicians blinded to group assignment." Judgement Comment: Low risk of bias for objective outcomes (muscle strength, walking test, fractures) High risk for subjective outcomes (quality of life)
Incomplete outcome data (attrition bias)	Low risk	Quote: "The intention-to-treat (ITT) analysis was performed using a linear mixed effects modeling approach implemented in the lme package for the R statistical computing environment." Judgement Comment: 3/29 dropped out in the exercise group vs 5/22 in the control group, reasons stated. Intention to treat analyses were performed.
Selective reporting (reporting bias)	High risk	Quote: "Self-reported physical function was measured using 3 separate instruments, each with different attributes. For comparison with commonly used questionnaires, we measured physical function with the Medical Outcomes Study 36-Item Short-Form Health Survey physical function subscale, a generic measure for use in general population surveys, and the physical function subscale of the European Organization for Research and Treatment of Cancer/Quality of Life Questionnaire (version 3), a cancer-specific measure." Judgement Comment: SF 36 were stated in the methods section but not reported in the publication
Other bias	Low risk	The study appears to be free of other sources of bias.

Footnotes

**Characteristics of excluded studies**

***Aggarwal 2015***

Reason for exclusion	Wrong intervention
----------------------	--------------------

***Alibhai 2015***

Reason for exclusion	A protocol
----------------------	------------

***Alibhai 2018***

Reason for exclusion	Only an abstract
----------------------	------------------

***Alibhai 2018a***

Reason for exclusion	A protocol
----------------------	------------

***Alibhai 2019***

Reason for exclusion	Wrong comparator
----------------------	------------------

***Armes 2016***

Reason for exclusion	Wrong intervention
----------------------	--------------------

***Baguley 2017***

Reason for exclusion	a protocol
----------------------	------------

***Bjorke 2020***

Reason for exclusion	Wrong study design
----------------------	--------------------

***Bourke 2018***

Reason for exclusion	Wrong patient population
----------------------	--------------------------

***Brady 2019***

Reason for exclusion	An abstract, wrong population and wrong outcomes
----------------------	--

***Buffart 2015***

Reason for exclusion	Wrong patient population
----------------------	--------------------------

***Cole 2017***

Reason for exclusion	Only an abstract
----------------------	------------------

***Cole 2017a***

Reason for exclusion	Only an abstract
----------------------	------------------

***Cormie 2013***

Reason for exclusion	Preliminary publication of a study. Primary publication already included Cormie 2015
----------------------	--

***Craike 2016***

Reason for exclusion	Wrong patient population
----------------------	--------------------------

***Craike 2018***

Reason for exclusion	Wrong patient population
----------------------	--------------------------

***Cunningham 2020***

Reason for exclusion	Wrong patient population
----------------------	--------------------------

***Dieperink 2013***

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Dieperink 2017**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Dorff 2017**

Reason for exclusion	Only an abstract
----------------------	------------------

**Doyle 2019**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Dunne 2019**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Dunne 2019a**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Edmunds 2020**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Eriksen 2017**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Fairman 2019**

Reason for exclusion	Wrong comparator
----------------------	------------------

**Focht 2019**

Reason for exclusion	Wrong outcomes
----------------------	----------------

**Frawley 2020**

Reason for exclusion	Wrong study design
----------------------	--------------------

**Freedland 2019**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Galvao 2014**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Galvao 2016**

Reason for exclusion	Only an abstract
----------------------	------------------

**Galvao 2017**

Reason for exclusion	Wrong study design
----------------------	--------------------

**Galvao 2017a**

Reason for exclusion	Only an abstract
----------------------	------------------

**Galvao 2018a**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Gaskin 2016**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Gaskin 2017**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Gilbert 2016**

Reason for exclusion	Wrong outcomes
----------------------	----------------

**Gray 2019**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Hart 2017**

Reason for exclusion	a protocol
----------------------	------------

**Hebert 2012**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Hojan 2015**

Reason for exclusion	Only an abstract
----------------------	------------------

**Hvid 2016**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Jones 2014**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Kenfield 2018**

Reason for exclusion	Only an abstract
----------------------	------------------

**Kim 2018**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Kiwata 2017**

Reason for exclusion	Only an abstract
----------------------	------------------

**Lam 2017**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Lam 2019**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Livingston 2015**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Lyons 2016**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Mareschal 2015**

Reason for exclusion	Wrong study design
----------------------	--------------------

**Martin 2015**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Martin 2016**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**McGowan 2013**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Monga 2007**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Mustian 2015**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Newton 2009**

Reason for exclusion	A protocol
----------------------	------------

**Newton 2012**

Reason for exclusion	a protocol
----------------------	------------

**Newton 2013**

Reason for exclusion	An abstract, full text already included Cormie 2015
----------------------	---

**Newton 2017**

Reason for exclusion	An abstract, full text already included, Taaffe 2017
----------------------	--

**Newton 2018**

Reason for exclusion	a protocol
----------------------	------------

**Newton 2019**

Reason for exclusion	a protocol
----------------------	------------

**Nilsen 2016**

Reason for exclusion	Wrong outcomes
----------------------	----------------

**Nilsen 2016a**

Reason for exclusion	Wrong outcomes
----------------------	----------------

**Nilsen 2018**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Norris 2015**

Reason for exclusion	Wrong comparator
----------------------	------------------

**Oneill 2015**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Oneill 2019**

Reason for exclusion	Wrong intervention
----------------------	--------------------



**Owen 2017**

Reason for exclusion	a protocol
----------------------	------------

**Papadopoulos 2020**

Reason for exclusion	Wrong comparator
----------------------	------------------

**Park 2012**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Park 2018**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Pernar 2017**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Saad 2016**

Reason for exclusion	a protocol
----------------------	------------

**Sajid 2016**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Schega 2015**

Reason for exclusion	Wrong study design
----------------------	--------------------

**Sheill 2017**

Reason for exclusion	a protocol
----------------------	------------

**Sheill 2019**

Reason for exclusion	Only an abstract
----------------------	------------------

**Singh 2017**

Reason for exclusion	Only an abstract
----------------------	------------------

**Taaffe 2018**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Teleni 2015**

Reason for exclusion	Wrong study design
----------------------	--------------------

**Uth 2016**

Reason for exclusion	Wrong outcomes
----------------------	----------------

**Uth 2016a**

Reason for exclusion	Wrong outcomes
----------------------	----------------

**Uth 2018**

Reason for exclusion	Wrong outcomes
----------------------	----------------

**Villumsen 2019**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Westley 2019**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Wilson 2017**

Reason for exclusion	Only an abstract
----------------------	------------------

**Windsor 2004**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

**Winters Stone 2015a**

Reason for exclusion	Wrong outcomes
----------------------	----------------

**Winters Stone 2016**

Reason for exclusion	Wrong intervention
----------------------	--------------------

**Zopf 2015**

Reason for exclusion	Wrong patient population
----------------------	--------------------------

*Footnotes*

**Characteristics of studies awaiting classification**

*Footnotes*

**Characteristics of ongoing studies**

*Footnotes*

**References to studies**

**Included studies**

**Bjerre 2019**

Bjerre, Eik; Bruun, Ditte Marie; Tolver, Anders; Brasso, Klaus; Krustup, Peter; Johansen, Christoffer; Christensen, Robin; Rorth, Mikael; Midtgaard, Julie. Effectiveness of community-based football compared to usual care in men with prostate cancer: Protocol for a randomised, controlled, parallel group, multicenter superiority trial (The FC Prostate Community Trial).. BMC Cancer 2016;16(1):767. [DOI: ]

Bjerre, Eik Dybboe; Brasso, Klaus; Jorgensen, Anders Bojer; Petersen, Thomas Hindborg; Eriksen, Alexandra Rothlin; Tolver, Anders; Christensen, Jesper Frank; Poulsen, Mads Hvid; Madsen, Soren Sorensen; Ostergren, Peter Busch; Borre, Michael; Krustup, Peter; Johansen, Christoffer; Rorth, Mikael; Midtgaard, Julie. Football Compared with Usual Care in Men with Prostate Cancer (FC Prostate Community Trial): A Pragmatic Multicentre Randomized Controlled Trial.. Sports Medicine 2019;49(1):145-158. [DOI: ]

Bjerre, Eik Dybboe; Petersen, Thomas Hindborg; Jorgensen, Anders Bojer; Johansen, Christoffer; Krustup, Peter; Langdahl, Bente; Poulsen, Mads Hvid; Madsen, Soren Sorensen; Ostergren, Peter Busch; Borre, Michael; Rorth, Mikael; Brasso, Klaus; Midtgaard, Julie. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial.. PLoS Medicine / Public Library of Science 2019;16(10):e1002936. [DOI: ]

**Bourke 2014**

Bourke L.; Gilbert S.; Hooper R.; Steed L. A.; Joshi M.; Catto J. W.; Saxton J. M.; Rosario D. J. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. *European urology* 2014;65(5):865-872. [DOI: 10.1016/j.eururo.2013.09.040 [doi]]

**Cormie 2015**

Cormie P.; Galvao D. A.; Spry N.; Joseph D.; Chee R.; Taaffe D. R.; Chambers S. K.; Newton R. U. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. *BJU international* 2015;115(2):256-266.

**Dawson 2018**

Dawson J. K.; Dorff T. B.; Todd Schroeder E.; Lane C. J.; Gross M. E.; Dieli-Conwright C. M. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. *BMC Cancer* 2018;18(368):Epub. [DOI: ]

Kiwata Jacqueline L.; Dorff Tanya B.; Todd Schroeder E.; Salem George J.; Lane Christianne J.; Rice Judd C.; Gross Mitchell E.; Dieli-Conwright Christina M. A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy. *BMJ Open* 2017;7(7):e016910. [DOI: ]

**Focht 2018**

Focht Brian C.; Lucas Alexander R.; Grainger Elizabeth; Simpson Christina; Fairman Ciaran M.; Thomas-Ahner Jennifer M.; Buell Jackie; Monk J. Paul; Mortazavi Amir; Clinton Steven K. Effects of a Group-Mediated Exercise and Dietary Intervention in the Treatment of Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Results From the IDEA-P Trial. *Annals of Behavioral Medicine* 2018;52(5):412-428. [DOI: ]

**Galvao 2010**

Galvao D. A.; Taaffe D. R.; Spry N.; Joseph D.; Newton R. U. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28(2):340-347. [DOI: 10.1200/JCO.2009.23.2488 [doi]]

**Galvao 2018**

Galvao Daniel A.; Taaffe Dennis R.; Spry Nigel; Cormie Prue; Joseph David; Chambers Suzanne K.; Chee Raphael; Peddle-McIntyre Carolyn J.; Hart Nicolas H.; Baumann Freerk T.; Denham James; Baker Michael; Newton Robert U. Exercise Preserves Physical Function in Prostate Cancer Patients with Bone Metastases. *Medicine & Science in Sports & Exercise* 2018;50(3):393-399. [DOI: ]

**Harrison 2018**

Harrison M.R.; Davis P.G.; Khouri M.G.; Gupta R. T.; Armstrong A.J.; McNamara M.A.; Zhang T.; Anand M.; Onyenwoke K.; Hood H.; Edvardson S.; Craig D.; Wu Y.; Healy P.; Coyne B.; Jones L.; George D. J. EXTEND: Safety and efficacy of exercise training in men receiving enzalutamide (ENZ) in combination with conventional androgen deprivation therapy (ADT) for hormone naive prostate cancer (HSPC). *Annals of Oncology* 2018;Conference(Journal Article):43r. [DOI: ]

**Hojan 2017**

Hojan Katarzyna; Kwiatkowska-Borowczyk Eliza; Leporowska Ewa; Gorecki Maciej; Ozga-Majchrzak Owidia; Milecki Tomasz; Milecki Piotr. Physical exercise for functional capacity, blood immune function, fatigue, and quality of life in high-risk prostate cancer patients during radiotherapy: a prospective, randomized clinical study. *European journal of physical & rehabilitation medicine* 2016;52(4):489-501. [DOI: ]

Hojan Katarzyna; Kwiatkowska-Borowczyk Eliza; Leporowska Ewa; Milecki Piotr. Inflammation, cardiometabolic markers, and functional changes in men with prostate cancer. A randomized controlled trial of a 12-month exercise program. *Polish Archives Of Internal Medicine* 2017;127(1):25-35. [DOI: ]

**Ndjavera 2020**

Ndjavera, Wilphard; Orange, Samuel T.; O'Doherty, Alasdair F.; Leicht, Anthony S.; Rochester, Mark; Mills, Robert; Saxton, John M.. Exercise-induced attenuation of treatment side-effects in patients with newly diagnosed prostate cancer beginning androgen-deprivation therapy: a randomised controlled trial.. *BJU international* 2020;125(1):28-37. [DOI: ]

**Newton 2020/Taaffe 2019**

Newton R.U.; Galvao D.A.; Spry N.; Joseph D.; Chambers S.K.; Gardiner R.A.; Hayne D.; Taaffe, D. R.. Timing of exercise for muscle strength and physical function in men initiating ADT for prostate cancer.. *Prostate Cancer and Prostatic Diseases* 2020;(pagination):ate of Pubaton: 2020. [DOI: ]

Taaffe, Dennis R.; Galvao, Daniel A.; Spry, Nigel; Joseph, David; Chambers, Suzanne K.; Gardiner, Robert A.; Hayne, Dickon; Cormie, Prue; Shum, David H. K.; Newton, Robert U.. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.. *BJU international* 2019;123(2):261-269. [DOI: ]

**Nilsen 2015**

Nilsen TS, Raastad T, Skovlund E, Courneya KS, Langberg CW, Lilleby W, Fosså SD, Thorsen L. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy. *Acta Oncol.* 2015 Nov;54(10):1805-13.

**Segal 2003**

Segal,R. J.; Reid,R. D.; Courneya,K. S.; Malone,S. C.; Parliament,M. B.; Scott,C. G.; Vennner,P. M.; Quinney,H. A.; Jones,L. W.; D'Angelo,M. E.; Wells,G. A.. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2003;21(9):1653-1659. [DOI: 10.1200/JCO.2003.09.534 [doi]]

**Segal 2009a**

Segal,R. J.; Reid,R. D.; Courneya,K. S.; Sigal,R. J.; Kenny,G. P.; Prud'Homme,D. G.; Malone,S. C.; Wells,G. A.; Scott,C. G.; Slovynec D'Angelo,M. E.. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009;27(3):344-351. [DOI: 10.1200/JCO.2007.15.4963 [doi]]

**Segal 2009b**

Segal,R. J.; Reid,R. D.; Courneya,K. S.; Sigal,R. J.; Kenny,G. P.; Prud'Homme,D. G.; Malone,S. C.; Wells,G. A.; Scott,C. G.; Slovynec D'Angelo,M. E.. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009;27(3):344-351.

**Taaffe2017/Newton 2019/Wall2017a**

Newton, Robert U.; Galvao, Daniel A.; Spry, Nigel; Joseph, David; Chambers, Suzanne K.; Gardiner, Robert A.; Wall, Brad A.; Bolam, Kate A.; Taaffe, Dennis R.. Exercise Mode Specificity for Preserving Spine and Hip Bone Mineral Density in Prostate Cancer Patients.. *Medicine & Science in Sports & Exercise* 2019;51(4):607-61404 2019.

Taaffe, Dennis R.; Newton, Robert U.; Spry, Nigel; Joseph, David; Chambers, Suzanne K.; Gardiner, Robert A.; Wall, Brad A.; Cormie, Prue; Bolam, Kate A.; Galvao, Daniel A.. Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial.. *European urology* 2017;72(2):293-299. [DOI: ]

Wall, Bradley A.; GALVaO, Daniel A.; Fatehee, Naeem; Taaffe, Dennis R.; Spry, Nigel; Joseph, David; Hebert, Jeffrey J.; Newton, Robert U.. Exercise Improves VO2max and Body Composition in Androgen Deprivation Therapy-treated Prostate Cancer Patients.. *Medicine & Science in Sports & Exercise* 2017;49(8):1503-151008 2017.

**Taaffe 2017/Newton 2019/Wall2017b**

Newton, Robert U.; Galvao, Daniel A.; Spry, Nigel; Joseph, David; Chambers, Suzanne K.; Gardiner, Robert A.; Wall, Brad A.; Bolam, Kate A.; Taaffe, Dennis R.. Exercise Mode Specificity for Preserving Spine and Hip Bone Mineral Density in Prostate Cancer Patients.. *Medicine & Science in Sports & Exercise* 2019;51(4):607-61404 2019.

Taaffe, Dennis R.; Newton, Robert U.; Spry, Nigel; Joseph, David; Chambers, Suzanne K.; Gardiner, Robert A.; Wall, Brad A.; Cormie, Prue; Bolam, Kate A.; Galvao, Daniel A.. Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial.. *European urology* 2017;72(2):293-299. [DOI: ]

Wall, Bradley A.; GALVaO, Daniel A.; Fatehee, Naeem; Taaffe, Dennis R.; Spry, Nigel; Joseph, David; Hebert, Jeffrey J.; Newton, Robert U.. Exercise Improves VO2max and Body Composition in Androgen Deprivation Therapy-treated Prostate Cancer Patients.. *Medicine & Science in Sports & Exercise* 2017;49(8):1503-151008 2017.

## **Uth 2014**

Uth,J.; Hornstrup,T.; Schmidt,J. F.; Christensen,J. F.; Frandsen,K. B.; Helge,E. W.; Brasso,K.; Rorth,M.; Midtgaard,J.; Krustup,P.. Football training improves lean body mass in men with prostate cancer undergoing androgen deprivation therapy. *Scandinavian Journal of Medicine & Science in Sports* 2014;24 Suppl 1(Journal Article):105-112. [DOI: 10.1111/sms.12260 [doi]]

## **Winters Stone 2015**

Winters-Stone, Kerri M.; Dobek, Jessica C.; Bennett, Jill A.; Dieckmann, Nathan F.; Maddalozzo, Gianni F.; Ryan, Christopher W.; Beer, Tomasz M.. Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: evidence from a randomized controlled trial.. *Archives of Physical Medicine & Rehabilitation* 2015;96(1):7-14. [DOI: ]

Winters-Stone K.M.; Dobek J.C.; Bennett J.A.; Maddalozzo G.F.; Ryan C.W.; Beer T.M.. Skeletal response to resistance and impact training in prostate cancer survivors. *Medicine and science in sports and exercise* 2014;46(8):1482-1488United States 2014.

## **Excluded studies**

### **Aggarwal 2015**

Aggarwal R.R.; Rodvelt T.J.; Rabow M.W.; Macaire G.; Fedric R.; CorteseJimenez G.; Small, E. J.. A multidisciplinary clinic to mitigate the impact of androgen deprivation therapy in prostate cancer: A pilot study.. *Journal of Clinical Oncology* 2015;Conference: 2015 Genitourinary Cancers Symposium. Orlando, FL United States. Conference Publication(var.pagings):ate of Pubaton: 01 Mar 2015. [DOI: ]

### **Alibhai 2015**

Alibhai,Shabbir M. H.; Santa Mina,Daniel; Ritvo,Paul; Sabiston,Catherine; Krahn,Murray; Tomlinson,George; Matthew,Andrew; Segal,Roanne; Warde,Padraig; Durbano,Sara; O'Neill,Meagan; Culos-Reed,Nicole. A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. *BMC Cancer* 2015;15(Journal Article):312England 2015.

### **Alibhai 2018**

Alibhai S.M.H.; Durbano S.; O'Neill M.; Mina D.S.; Ritvo P.; Sabiston C.; Krahn M.D.; Tomlinson G.A.; Matthew A.; Warde P.R.; Timilshina N.; Segal R.; Nicole CulosReed, S.. Effects of a 6-month moderate-intensity exercise program on metabolic parameters and bone mineral density in men on androgen deprivation therapy for prostate cancer.. *Journal of Clinical Oncology* 2018;Conference: 2018 Genitourinary Cancers Symposium. United States(Journal Article);ate of Pubaton: February 2018. [DOI: ]

### **Alibhai 2018a**

Alibhai, Shabbir M. H.; Ritvo, Paul; Santa Mina, Daniel; Sabiston, Catherine; Krahn, Murray; Tomlinson, George; Matthew, Andrew; Lukka, Himu; Warde, Padraig; Durbano, Sara; O'Neill, Meagan; Culos-Reed, S.. Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT. *BMC Cancer* 2018;18(1):1-18. [DOI: 10.1186/s12885-018-4937-x]

### **Alibhai 2019**

Alibhai, Shabbir M. H.; Santa Mina, Daniel; Ritvo, Paul; Tomlinson, George; Sabiston, Catherine; Krahn, Murray; Durbano, Sara; Matthew, Andrew; Warde, Padraig; O'Neill, Meagan; Nathari; Segal, Roanne; Culos-Reed, Nicole. A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy. *BMC Cancer* 2019;19(1):1-11. [DOI: 10.1186/s12885-018-5189-5]

**Armes 2016**

Armes J.; Harris J.; Tsianakas V.; Ream E.; Van Hemelrijck M.; Green J.; Purushotham A.; Mucci L.; Robb K.; Fewster, J.. Can walk: A randomised feasibility trial of a walking intervention for people with recurrent or metastatic cancer.. Psycho-oncology 2016;Conference: 2016 World Congress of Psycho-Oncology. Ireland(Journal Article);ate of Pubaton: October 2016. [DOI: ]

**Baguley 2017**

Baguley, Brenton J.; Skinner, Tina L.; Leveritt, Michael D.; Wright, Olivia R. L.. Nutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: a study protocol. BMC Cancer 2017;17(Journal Article);1-12. [DOI: 10.1186/s12885-016-3022-6]

**Bjorke 2020**

Bjorke, Ann Christin Helgesen; Raastad, Truls; Berntsen, Sveinung. Criteria for the determination of maximal oxygen uptake in patients newly diagnosed with cancer: Baseline data from the randomized controlled trial of physical training and cancer (Phys-Can).. PLoS ONE [Electronic Resource] 2020;15(6):e0234507. [DOI: ]

**Bourke 2018**

Bourke, L.; Stevenson, R.; Turner, R.; Hooper, R.; Sasieni, P.; Greasley, R.; Morrissey, D.; Loosemore, M.; Fisher, A.; Payne, H.; Taylor, S. J. C.; Rosario, D. J.. Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study.. Scientific Reports 2018;8(1):8374. [DOI: ]

**Brady 2019**

Brady L.; Hayes B.; Sheill G.; Baird A.M.; Guinan E.M.; Stanfill B.; Vlahjic T.; Casey O.; Greene J.P.; Allott E.; Hussey J.M.; Cahill F.; Van Hemelrijck M.; Peat N.; Rudman S.M.; Mucci L.; Sheils O.; John O.; McDermott R.; Finn, S. P.. The effect of a structured exercise intervention on CTCs and platelet cloaking in patients with metastatic prostate cancer.. American Society of Clinical Oncology. Journal of Clinica Oncology. Volumen 37, Issue 7, Suppl..

**Buffart 2015**

Buffart, Laurien M.; Newton, Robert U.; Chinapaw, Mai J.; Taaffe, Dennis R.; Spry, Nigel A.; Denham, James W.; Joseph, David J.; Lamb, David S.; Brug, Johannes; Galvao, Daniel A.. The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer.. Cancer 2015;121(16):2821-2830. [DOI: ]

**Cole 2017**

Cole C.; Peppone L.J.; Kleckner I.; Lin P.J.; Dunne R.F.; Fung C.; Loh K.P.; Asare M.; Mustian K.M.; Morrow, G. R.. Effects of exercise on dyspnea and cancer-related fatigue in patients with prostate cancer.. Journal of Clinical Oncology 2017;Conference: 2017 Annual Meeting of the American Society of Clinical Oncology, ASCO. United States(Journal Article);ate of Pubaton: 20 Jun 2017. [DOI: ]

**Cole 2017a**

Cole C.; Peppone L.; Kamen C.; Fung C.; Loh K.; Dunn R.; Kleckner I.; Lin P.J.; Asare M.; Janelsins M.; Mustian, K.. Interrelationship between improvements in aerobic capacity and cancer-related-fatigue in prostate cancer patients.. Supportive Care in Cancer 2017;Conference: 2017 International MASCC/ISOO Symposium: Supportie Care in Cancer. United States(Journal Article);ate of Pubaton: 2017. [DOI: ]

**Cormie 2013**

Cormie,P.; Newton,R. U.; Spry,N.; Joseph,D.; Taaffe,D. R.; Galvao,D. A.. Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate cancer and prostatic diseases 2013;16(4):328-335. [DOI: 10.1038/pcan.2013.22 [doi]]

**Craike 2016**

Craike, Melinda J.; Cadeyrm J.; Courneya, Kerry S.; Fraser, Steve F.; Salmon, Jo; Owen, Patrick J.; Broadbent, Suzanne; Livingston, Patricia M.. Predictors of adherence to a 12-week exercise program among men treated for prostate cancer: ENGAGE study.. *Cancer Medicine* 2016;5(5):787-794. [DOI: ]

**Craike 2018**

Craike, Melinda J.; Gaskin, Cadeyrm J.; Mohebbi, Mohammadreza; Courneya, Kerry S.; Livingston, Patricia M.. Mechanisms of Physical Activity Behavior Change for Prostate Cancer Survivors: A Cluster Randomized Controlled Trial.. *Annals of Behavioral Medicine* 2018;52(9):798-808. [DOI: ]

**Cunningham 2020**

Cunningham E.; Weaver R.R.; Lemonde M.; Dogra S.; Nonoyama, M. L.. Nordic Pole Walking for Individuals with Cancer: A Feasibility Randomized Controlled Trial Assessing Physical Function and Health-Related Quality of Life.. *Rehabilitation Oncology* 2020;38(2):81-91. [DOI: ]

**Dieperink 2013**

Dieperink, K. B.; Johansen, C.; Hansen, S.; Wagner, L.; Andersen, K. K.; Minet, L. R.; Hansen, O.. The effects of multidisciplinary rehabilitation: RePCa-a randomised study among primary prostate cancer patients. *British journal of cancer* 2013;109(12):3005-3013. [DOI: 10.1038/bjc.2013.679 [doi]]

**Dieperink 2017**

Dieperink, Karin B.; Johansen, Christoffer; Hansen, Steinbjorn; Wagner, Lis; K Andersen, Klaus; Minet, Lisbeth R.; Hansen, Olfred. Male coping through a long-term cancer trajectory. Secondary outcomes from a RTC examining the effect of a multidisciplinary rehabilitation program (RePCa) among radiated men with prostate cancer.. *Acta Oncologica* 2017;56(2):254-261. [DOI: ]

**Dorff 2017**

Dorff T.; Gross M.; Quinn D.I.; Pinski J.; Schroeder T.; Groshen S.; DieliConwright C.; Kiwata, J.. Impact of resistance exercise on metabolic syndrome (MetS) parameters in men receiving androgen deprivation therapy (ADT) for prostate cancer.. *Annals of Oncology* 2017;Conference(Journal Article):42n. [DOI: ]

**Doyle 2019**

Doyle C.P.; Thirion P.; O'Neill B.; Dunne M.; Curtis, V.. P2 RCT of Home-based physical activity in pts treated by ADT and EBRT for localised prostate carcinoma.. *Radiotherapy and Oncology* 2019;Conference: ESTRO 38: Targeting optimal care, together. Italy(Journal Article):ate of Pubaton: Ar 2019. [DOI: ]

**Dunne 2019**

Dunne R.F.; Heckler C.E.; Inglis J.E.; Lin P.J.; Fung C.; Peppone L.J.; Lopez G.; Culakova E.; Kleckner I.; Janelsins M.C.; Jatoi A.; Mohile S.G.; Mustian, K. M.. Evaluating the effects of a structured exercise intervention on physical self-worth in men with prostate cancer: Addressing an unmet need.. *Journal of Clinical Oncology* 2019;Conference(Journal Article):2019. [DOI: ]

**Dunne 2019a**

Dunne R.; Heckler C.; Inglis J.; Lin P.J.; Fung C.; Peppone L.; Lopez G.; Culakova E.; Kleckner I.; Janelsins M.; Jatoi A.; Mohile S.; Mustian, K.. Assessing the impact of a structured exercise intervention on physical self-worth in men with prostate cancer: A randomized controlled trial.. *Supportive Care in Cancer* 2019;Conference: 2019 Joint Meeting of the Multinational Association of Supportive Care in Cancer, MASCC and the International Society of Oral Oncology, ISOO. United States(Journal Article):ate of Pubaton: June 2019. [DOI: ]



**Edmunds 2020**

Edmunds, Kim; Reeves, Penny; Scuffham, Paul; Galvao, Daniel A.; Newton, Robert U.; Jones, Mark; Spry, Nigel; Taaffe, Dennis R.; Joseph, David; Chambers, Suzanne K.; Tuffaha, Haitham. Cost-Effectiveness Analysis of Supervised Exercise Training in Men with Prostate Cancer Previously Treated with Radiation Therapy and Androgen-Deprivation Therapy.. *Applied Health Economics & Health Policy* 2020;(Journal Article). [DOI: ]

**Eriksen 2017**

Eriksen, A. K.; Hansen, R. D.; Larsen, R. G.; Jensen, J. M.; Overgaard, K.; Borre, M.; Kyro, C.; Landberg, R.; Olsen, A.; Tjonneland, A.. A lifestyle intervention among elderly men on active surveillance for non-aggressive prostate cancer: a randomised feasibility study with whole-grain rye and exercise. *Trials* 2017;18(20):Epub. [DOI: ]

**Fairman 2019**

Fairman, Ciaran M.; Kendall, Krissy L.; Newton, Robert U.; Hart, Nicolas H.; Taaffe, Dennis R.; Chee, Raphael; Tang, Colin I.; Galvao, Daniel A.. Examining the effects of creatine supplementation in augmenting adaptations to resistance training in patients with prostate cancer undergoing androgen deprivation therapy: a randomised, double-blind, placebo-controlled trial.. *BMJ Open* 2019;9(9):e030080. [DOI: ]

**Focht 2019**

Focht, Brian C.; Lucas, Alexander R.; Grainger, Elizabeth; Simpson, Christina; Fairman, Ciaran M.; Thomas-Ahner, Jennifer M.; Chaplow, Zachary L.; DeScenza, Victoria R.; Bowman, Jessica; Clinton, Steven K.. Effects of a Group-Mediated Cognitive Behavioral Lifestyle Intervention on Select Social Cognitive Outcomes in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy.. *Integrative Cancer Therapies* 2019;18(Journal Article):1534735419893764. [DOI: ]

**Frawley 2020**

Frawley, Helena C.; Lin, Kuan-Yin; Granger, Catherine L.; Higgins, Rosemary; Butler, Michael; Denehy, Linda. An allied health rehabilitation program for patients following surgery for abdomino-pelvic cancer: a feasibility and pilot clinical study.. *Supportive Care in Cancer* 2020;28(3):1335-1350. [DOI: ]

**Freedland 2019**

Freedland, Stephen J.; Howard, Lauren; Allen, Jennifer; Stout, Jordan; Smith, Jennifer; Aronson, William; Inman, Brant A.; Armstrong, Andrew J.; George, Daniel; Westman, Eric; Lin, Pao-Hwa. A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.. *Prostate Cancer & Prostatic Diseases* 2019;22(3):428-437. [DOI: ]

**Galvao 2014**

Galvao, D. A.; Spry, N.; Denham, J.; Taaffe, D. R.; Cormie, P.; Joseph, D.; Lamb, D. S.; Chambers, S. K.; Newton, R. U.. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. *European urology* 2014;65(5):856-864. [DOI: 10.1016/j.eururo.2013.09.041 [doi]]

**Galvao 2016**

Galvao, D.. Exercise as a synergistic medicine for prostate cancer.. *Asia-Pacific Journal of Clinical Oncology* 2016;Conference: Annual Scientific Meeting of the Australian and New Zealand Urogenital and Prostate, GU Cancer: Expanding our Horizons, ANZUP 2016. *Australia(Journal Article):ate of Pubaton: July 2016. [DOI: ]*

**Galvao 2017**

Galvao D.A.; Taaffe D.R.; Spry N.; Cormie P.; Joseph D.; Chambers S.K.; PeddleMcintyre C.; Hart N.H.; Denham J.; Baker M.; Newton, R. U.. Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: A randomized controlled trial.. *BJU international* 2017;Conference(Journal Article):18th. [DOI: ]

**Galvao 2017a**

Galvao, D.. Exercise as a synergistic medicine for cancer.. Clinical endocrinology 2017;Conference(Journal Article):Enome. [DOI: ]

**Galvao 2018a**

Galvao, Daniel A.; Hayne, Dickon; Frydenberg, Mark; Chambers, Suzanne K.; Taaffe, Dennis R.; Spry, Nigel; Scuffham, Paul A.; Ware, Robert S.; Hart, Nicolas H.; Newton, Robert U.. Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial.. *BMJ Open* 2018;8(4):e022331. [DOI: ]

**Gaskin 2016**

Gaskin, Cadey M J.; Fraser, Steve F.; Owen, Patrick J.; Craike, Melinda; Orellana, Liliana; Livingston, Patricia M.. Fitness outcomes from a randomised controlled trial of exercise training for men with prostate cancer: the ENGAGE study.. *Journal of Cancer Survivorship* 2016;10(6):972-980. [DOI: ]

**Gaskin 2017**

Gaskin, Cadey M J.; Craike, Melinda; Mohebbi, Mohammadreza; Courmeya, Kerry S.; Livingston, Patricia M.. A Clinician Referral and 12-Week Exercise Training Program for Men With Prostate Cancer: Outcomes to 12 Months of the ENGAGE Cluster Randomized Controlled Trial.. *Journal of Physical Activity & Health* 2017;14(5):353-359. [DOI: ]

**Gilbert 2016**

Gilbert, Stephen E.; Tew, Garry A.; Fairhurst, Caroline; Bourke, Liam; Saxton, John M.; Winter, Edward M.; Rosario, Derek J.. Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer.. *British journal of cancer* 2016;114(4):401-408. [DOI: ]

**Gray 2019**

Gray, Marquita S.; Judd, Suzanne E.; Sloane, Richard; Snyder, Denise C.; Miller, Paige E.; Demark-Wahnefried, Wendy. Rural-urban differences in health behaviors and outcomes among older, overweight, long-term cancer survivors in the RENEW randomized control trial.. *Cancer Causes & Control* 2019;30(4):301-309. [DOI: ]

**Hart 2017**

Hart, Nicolas H.; Newton, Robert U.; Spry, Nigel A.; Taaffe, Dennis R.; Chambers, Suzanne K.; Feeney, Kynan T.; Joseph, David J.; Redfern, Andrew D.; Ferguson, Tom; Galvao, Daniel A.. Can exercise suppress tumour growth in advanced prostate cancer patients with sclerotic bone metastases? A randomised, controlled study protocol examining feasibility, safety and efficacy.. *BMJ Open* 2017;7(5):e014458. [DOI: ]

**Hebert 2012**

Hebert, J. R.; Hurley, T. G.; Harmon, B. E.; Heiney, S.; Hebert, C. J.; Steck, S. E.. A diet, physical activity, and stress reduction intervention in men with rising prostate-specific antigen after treatment for prostate cancer. *Cancer epidemiology* 2012;36(2):e128-36. [DOI: 10.1016/j.canep.2011.09.008 [doi]]

**Hojan 2015**

Hojan K.; Milecki P.; KwiatkowskaBorowczyk E.; Leporowska, E.. Physical exercises, inflammation, fatigue and aerobic fitness in prostate cancer patients undergoing antiandrogen-and radiotherapy.. *Archives of Physical Medicine and Rehabilitation*. Conference: 2015 American Congress of Rehabilitation Medicine Annual Conference, ACRM 2015.Dallas, TX United States. Conference Publication: (var.pagings) 2015;96(10):e5. [DOI: ]

**Hvid 2016**

[Other: ]

Hvid,Thine; Lindegaard,Birgitte; Winding,Kamilla; Iversen,Peter; Brasso,Klaus; Solomon,Thomas P. J.; Pedersen,Bente K.; Hojman,Pernille. Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients.. *Cancer Causes & Control* 2016;27(2):165-174Netherlands 2016.

**Jones 2014**

Jones,L. W.; Hornsby,W. E.; Freedland,S. J.; Lane,A.; West,M. J.; Moul,J. W.; Ferrandino,M. N.; Allen,J. D.; Kenjale,A. A.; Thomas,S. M.; Herndon,J. E.,2nd; Koontz,B. F.; Chan,J. M.; Khouri,M. G.; Douglas,P. S.; Eves,N. D.. Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer. *European urology* 2014;65(5):852-855. [DOI: 10.1016/j.eururo.2013.11.009 [doi]]

**Kenfield 2018**

Kenfield S.A.; Blarigan E.V.; Ameli N.; Lavaki E.; Monroy C.; Tantum L.K.; Newton R.U.; Zhang L.; Cooperberg M.R.; Carroll P.; Chan, J. M.. Prostate 8 study: A pilot randomized controlled trial (RCT) of a web-based lifestyle intervention versus control group among men with prostate cancer.. *Journal of Clinical Oncology* 2018;Conference: 2018 Genitourinary Cancers Symposium. United States(Journal Article);ate of Pubaton: February 2018. [DOI: ]

**Kim 2018**

Kim, Soo Hyun; Seong, Do Hwan; Yoon, Sang Min; Choi, Young Deuk; Song, Eunju; Song, Youngkyu; Song, Hosook. The Effect on Bone Outcomes of Home-based Exercise Intervention for Prostate Cancer Survivors Receiving Androgen Deprivation Therapy: A Pilot Randomized Controlled Trial.. *Cancer nursing* 2018;41(5):379-388. [DOI: ]

**Kiwata 2017**

Kiwata J.L.; Dorff T.B.; Schroeder E.T.; DieliConwright, C. M.. Effect of a supervised exercise intervention on sarcopenic obesity and metabolic syndrome in prostate cancer patients: A randomized pilot study.. *Cancer research* 2017;Conference(Journal Article);Aneran. [DOI: ]

**Lam 2017**

Lam T.; Cheema B.; Hayden A.; Gurney H.; Gounden S.; Reddy N.; Stone G.; McLean M.; Birzniece, V.. ADT in prostate cancer patients: Prevention of adverse effects using a 6-month home-based progressive resistance training program.. *Clinical endocrinology* 2017;Conference(Journal Article);Enorne. [DOI: ]

**Lam 2019**

Lam, Teresa; McLean, Mark; Hayden, Amy; Poljak, Anne; Cheema, Birinder; Gurney, Howard; Stone, Glenn; Bahl, Neha; Reddy, Navneeta; Shahidipour, Haleh; Birzniece, Vita. A potent liver-mediated mechanism for loss of muscle mass during androgen deprivation therapy.. *Endocrine Connections* 2019;8(5):605-615. [DOI: ]

**Livingston 2015**

Livingston, Patricia M.; Craike, Melinda J.; Salmon, Jo; Courmeya, Kerry S.; Gaskin, Cadeym J.; Fraser, Steve F.; Mohebbi, Mohammadreza; Broadbent, Suzanne; Botti, Mari; Kent, Bridie; ENGAGE Uro-Oncology Clinicians' Group. Effects of a clinician referral and exercise program for men who have completed active treatment for prostate cancer: A multicenter cluster randomized controlled trial (ENGAGE).. *Cancer* 2015;121(15):2646-2654. [DOI: ]

**Lyons 2016**

Lyons, Karen S.; Winters-Stone, Kerri M.; Bennett, Jill A.; Beer, Tomasz M.. The effects of partnered exercise on physical intimacy in couples coping with prostate cancer.. *Health Psychology* 2016;35(5):509-513. [DOI: ]

**Mareschal 2015**

Mareschal J.; Frambati L.; Blason E.; PhilippParadisi S.; Rigoli P.; Weber K.; Zilli T.; Miralbell R.; Pichard, C.. Prostate cancer and androgen deprivation in frail patients: A 2YR prospective multidisciplinary program. Preliminary data.. Supportive Care in Cancer.Conference: 2015 International MASCC/ISOO Symposium: Supportive Care in Cancer.Copenhagen Denmark.Conference Publication: (var.pagings) 2015;23(1 SUPPL. 1):S277. [DOI: ]

**Martin 2015**

Martin, Eric A.; Battaglini, Claudio L.; Hands, Beth; Naumann, Fiona. Higher-Intensity Exercise Results in More Sustainable Improvements for VO2peak for Breast and Prostate Cancer Survivors.. Oncology nursing forum 2015;42(3):241-249. [DOI: ]

**Martin 2016**

Martin, Eric; Battaglini, Claudio; Hands, Beth; Naumann, Fiona L.. Higher-intensity exercise helps cancer survivors remain motivated.. Journal of Cancer Survivorship 2016;10(3):524-533. [DOI: ]

**McGowan 2013**

McGowan,E. L.; North,S.; Courneya,K. S.. Randomized controlled trial of a behavior change intervention to increase physical activity and quality of life in prostate cancer survivors. Annals of Behavioral Medicine : A Publication of the Society of Behavioral Medicine 2013;46(3):382-393. [DOI: 10.1007/s12160-013-9519-1 [doi]]

**Monga 2007**

Monga,U.; Garber,S. L.; Thornby,J.; Vallbona,C.; Kerrigan,A. J.; Monga,T. N.; Zimmermann,K. P.. Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy. Archives of Physical Medicine and Rehabilitation 2007;88(11):1416-1422. [DOI: S0003-9993(07)01448-7 [pii]]

**Mustian 2015**

Mustian K.; Janeloins M.; Peppone L.; Kamen C.; Heckler, C.. Exercise effects on muscular strength, cancer-related fatigue, and mitochondrial and nuclear gene expression in skeletal muscle among older prostate cancer patients.. Supportive Care in Cancer.Conference: 2015 International MASCC/ISOO Symposium: Supportive Care in Cancer.Copenhagen Denmark.Conference Publication: (var.pagings) 2015;23(1 SUPPL. 1):S89-S90. [DOI: ]

**Newton 2009**

Newton,Robert U.; Taaffe,Dennis R.; Spry,Nigel; Gardiner,Robert A.; Levin,Gregory; Wall,Bradley; Joseph,David; Chambers,Suzanne K.; Galvao,Daniel A.. A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer.. BMC Cancer 2009;9(Journal Article);210England 2009.

**Newton 2012**

[Other: ]

Newton,Robert U.; Taaffe,Dennis R.; Spry,Nigel; Cormie,Prue; Chambers,Suzanne K.; Gardiner,Robert A.; Shum,David Hk; Joseph,David; Galvao,Daniel A. Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation? BMC Cancer 2012;12(Journal Article);432England 2012.

**Newton 2013**

Newton R.; Cormie P.; Galvao D.; Spry N.; Joseph D. Can exercise prevent treatment toxicity in prostate cancer patients initiating androgen suppression therapy: A randomised controlled trial. BJU international 2013;112(Web Page);63Blackwell Publishing Ltd 2013.

**Newton 2017**

Newton R.U.; Galvao D.A.; Spry N.; Joseph D.; Chambers S.K.; Gardiner R.A.; Hayne D.; Hart N.H.; Wall B.A.; Bolam K.A.; Taaffe, D. R.. Exercise medicine to arrest bone loss in men with prostate cancer undergoing androgen deprivation therapy: A 12-month randomized controlled trial.. *BJU international* 2017; Conference(Journal Article):18th. [DOI: ]

**Newton 2018**

Newton, Robert U.; Kenfield, Stacey A.; Hart, Nicolas H.; Chan, June M.; Coumeya, Kerry S.; Catto, James; Finn, Stephen P.; Greenwood, Rosemary; Hughes, Daniel C.; Mucoi, Lorelei; Plymate, Stephen R.; Praet, Stephan F. E.; Guinan, Emer M.; Van Blarigan, Erin L.; Casey, Orla; Buzza, Mark; Gledhill, Sam; Zhang, Li; Galvao, Daniel A.; Ryan, Charles J.; Saad, Fred. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.. *BMJ Open* 2018;8(5):e022899. [DOI: ]

**Newton 2019**

Newton, Robert U.; Christophersen, Claus T.; Fairman, Ciaran M.; Hart, Nicolas H.; Taaffe, Dennis R.; Broadhurst, David; Devine, Amanda; Chee, Raphael; Tang, Colin I.; Spry, Nigel; Galvao, Daniel A.. Does exercise impact gut microbiota composition in men receiving androgen deprivation therapy for prostate cancer? A single-blinded, two-armed, randomised controlled trial.. *BMJ Open* 2019;9(4):e024872. [DOI: ]

**Nilsen 2016**

Nilsen T.S.; Thorsen L.; Kirkegaard C.; Ugelstad I.; Fossa S.D.; Raastad, T.. The effect of strength training on muscle cellular stress in prostate cancer patients on ADT.. *Endocrine Connections* 2016;5(2):74-82. [DOI: ]

**Nilsen 2016a**

Nilsen, T. S.; Thorsen, L.; Fossa, S. D.; Wiig, M.; Kirkegaard, C.; Skovlund, E.; Benestad, H. B.; Raastad, T.. Effects of strength training on muscle cellular outcomes in prostate cancer patients on androgen deprivation therapy.. *Scandinavian Journal of Medicine & Science in Sports* 2016;26(9):1026-1035. [DOI: ]

**Nilsen 2018**

Nilsen, Tormod S.; Scott, Jessica M.; Michalski, Meghan; Capaci, Catherine; Thomas, Samantha; Herndon, James E. 2nd; Sasso, John; Eves, Neil D.; Jones, Lee W.. Novel Methods for Reporting of Exercise Dose and Adherence: An Exploratory Analysis.. *Medicine & Science in Sports & Exercise* 2018;50(6):1134-1141. [DOI: ]

**Norris 2015**

Norris, M. K.; Bell, G. J.; North, S.; Courneya, K. S.. Effects of resistance training frequency on physical functioning and quality of life in prostate cancer survivors: a pilot randomized controlled trial.. *Prostate Cancer & Prostatic Diseases* 2015;18(3):281-287. [DOI: ]

**Oneill 2015**

O'Neill, Roisin F.; Haseen, Farhana; Murray, Liam J.; O'Sullivan, Joe M.; Cantwell, Marie M.. A randomised controlled trial to evaluate the efficacy of a 6-month dietary and physical activity intervention for patients receiving androgen deprivation therapy for prostate cancer.. *Journal of Cancer Survivorship* 2015;9(3):431-440. [DOI: ]

**Oneill 2019**

Oneill M.; Santa Mina D.; Sabiston C.; Tomlinson G.; Alibhai, S. M.. BENEFITS OF PHYSICAL ACTIVITY ON REDUCING CANCER-RELATED FATIGUE FOR OLDER MEN WITH PROSTATE CANCER: A RANDOMIZED CONTROLLED TRIAL.. *Journal of Geriatric Oncology* 2019;Conference(Journal Article):19th. [DOI: ]

**Owen 2017**

Owen, Patrick J.; Daly, Robin M.; Livingston, Patricia M.; Mundell, Niamh L.; Dalla Via, Jack; Millar, Jeremy L.; Fraser, Steve F.. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.. *Trials* [Electronic Resource] 2017;18(1):451. [DOI: ]

**Papadopoulos 2020**

Papadopoulos, Effthymios; Mina, Daniel Santa; Culos-Read, Nicole; Durbano, Sara; Ritvo, Paul; Sabiston, Catherine M.; Krahn, Murray; Tomlinson, George; O'Neill, Meagan; Timilshina, Narhari; Matthew, Andrew; Warde, Padraig; Alibhai, Shabbir M. H.. Effects of six months of aerobic and resistance training on metabolic markers and bone mineral density in older men on androgen deprivation therapy for prostate cancer.. *Journal of Geriatric Oncology* 2020;(Journal Article). [DOI: ]

**Park 2012**

Park, S. W.; Kim, T. N.; Nam, J. K.; Ha, H. K.; Shin, D. G.; Lee, W.; Kim, M. S.; Chung, M. K.. Recovery of overall exercise ability, quality of life, and continence after 12-week combined exercise intervention in elderly patients who underwent radical prostatectomy: a randomized controlled study. *Urology* 2012;80(2):299-305. [DOI: 10.1016/j.urology.2011.12.060 [doi]]

**Park 2018**

Park Y.H.; Lee J.I.; Lee J.Y.; Cheong I.Y.; Hwang J.H.; Seo S.I.; Lee K.H.; Yoo J.S.; Chung S.H.; Ko Y.S.; Lee Y.H.; Lee, S. I.. Internet- and mobile-based lifestyle intervention for prostate cancer patients on androgen deprivation therapy: Prospective, multicenter, randomized trial.. *Journal of Clinical Oncology* 2018;Conference(Journal Article):2018. [DOI: ]

**Pernar 2017**

Pernar, Claire H.; Fall, Katja; Rider, Jennifer R.; Markt, Sarah C.; Adami, Hans-Olov; Andersson, Sven-Olof; Valdimarsdottir, Unnur; Andren, Ove; Mucci, Lorelei A.. A Walking Intervention Among Men With Prostate Cancer: A Pilot Study.. *Clinical Genitourinary Cancer* 2017;15(6):e1021-e1028. [DOI: ]

**Saad 2016**

Saad F.; Kenfield S.A.; Chan J.M.; Hart N.H.; Courneya K.S.; Catto J.; Finn S.P.; Greenwood R.; Hughes D.C.; Mucci L.A.; Plymate S.R.; Pollak M.N.; Praet S.F.E.; Russell A.P.; Guinan E.M.; Van Blarigan E.; Casey O.; Buzza M.; Ryan C.J.; Newton, R. U.. Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL - MCRPC): A Movember funded multicenter, randomized, controlled phase III study.. *Journal of Clinical Oncology* 2016;Conference(Journal Article):2016. [DOI: ]

**Sajid 2016**

Sajid, Saleha; Dale, William; Mustian, Karen; Kotwal, Ashwin; Heckler, Charles; Porto, Michelle; Fung, Chunkit; Mohile, Supriya G.. Novel physical activity interventions for older patients with prostate cancer on hormone therapy: A pilot randomized study.. *Journal of Geriatric Oncology* 2016;7(2):71-80. [DOI: ]

**Schega 2015**

Schega, Lutz; Torpel, Alexander; Hein, Nico; Napiontek, Andre; Wenzel, Constanze; Becker, Tim. Evaluation of a supervised multi-modal physical exercise program for prostate cancer survivors in the rehabilitation phase: Rationale and study protocol of the ProCaLife study.. *Contemporary Clinical Trials* 2015;45(Pt B):311-319. [DOI: ]

**Sheill 2017**

Sheill, Grainne; Brady, Lauren; Guinan, Emer; Hayes, Brian; Casey, Orla; Greene, John; Vlajnic, Tatjana; Fidelity, Cahill, Fidelma; Van Hemelryck, Mieke; Peat, Nicola; Rudman, Sarah; Hussey, Juliette; Cunningham, Moya; Grogan, Liam; Lynch, Thomas; Manecksha, Rustom P.; McCaffrey, John; Mucci, Lorelei; Sheils, Orla; O'Leary, John; O'Donnell, Dearbhla M.; McDermott, Ray; Finn, Stephen. The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial.. *Trials* [Electronic Resource] 2017;18(1):456. [DOI: ]

**Sheill 2019**

Sheill G.; Brady L.; Guinan E.M.; Hussey J.M.; Hayes B.; Baird A.M.; Stanfill B.; Casey O.; Murphy V.; Rudman S.M.; Peat N.; Sheils O.; Cahill F.; Van Hemelrijck M.; McCaffrey J.; aO'Donnell D.M.; Mucci L.; Grogan W.; McDermott R.; Finn, S. P. A randomized trial of exercise on quality of life in men with metastatic prostate cancer: The EXPeCT Trial.. Journal of Clinical Oncology 2019;Conference: 2019 Supportive Care in Oncology Symposium. United States(Journal Article):ate of Pubaton: Noember 2019. [DOI: ]

**Singh 2017**

Singh F.; Newton R.U.; Taaffe D.R.; Spry N.; Joseph D.; Chambers S.K.; Gardiner R.A.; Galvao, D. A.. Year-long study evaluating the effect of exercise on quality of life and psychological distress in men with prostate cancer undergoing androgen deprivation therapy.. BJU international 2017;Conference(Journal Article):18th. [DOI: ]

**Taaffe 2018**

Taaffe, Dennis R.; Buffart, Laurien M.; Newton, Robert U.; Spry, Nigel; Denham, James; Joseph, David; Lamb, David; Chambers, Suzanne K.; Galvao, Daniel A.. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.. BJU international 2018;12(2):194-202. [DOI: ]

**Teleni 2015**

Teleni L.; Chan R.; Chan A.; Isenring E.A.; Vela I.; Inder W.J.; McCarthy, A. L.. Dietary and exercise interventions to improve quality of life, metabolic risk factors and androgen deficiency symptoms in men with prostate cancer undergoing androgen deprivation therapy.. Supportive Care in Cancer.Conference: 2015 International MASCC/ISOO Symposium: Supportive Care in Cancer.Copenhagen Denmark.Conference Publication: (var.pagings) 2015;23(1 SUPPL. 1):S171. [DOI: ]

**Uth 2016**

Uth, J.; Hornstrup, T.; Christensen, J. F.; Christensen, K. B.; Jorgensen, N. R.; Schmidt, J. F.; Brasso, K.; Jakobsen, M. D.; Sundstrup, E.; Andersen, L. L.; Rorth, M.; Midtgaard, J.; Krustup, P.; Helge, E. W.. Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.. Osteoporosis International 2016;27(4):1507-1518. [DOI: ]

**Uth 2016a**

Uth, Jacob; Hornstrup, Therese; Christensen, Jesper F.; Christensen, Karl B.; Jorgensen, Niklas R.; Helge, Eva W.; Schmidt, Jakob F.; Brasso, Klaus; Helge, Jorn W.; Jakobsen, Markus D.; Andersen, Lars L.; Rorth, Mikael; Midtgaard, Julie; Krustup, Peter. Football training in men with prostate cancer undergoing androgen deprivation therapy: activity profile and short-term skeletal and postural balance adaptations.. European journal of applied physiology 2016;116(3):471-480. [DOI: ]

**Uth 2018**

Uth, J.; Fristrup, B.; Haahr, R. D.; Brasso, K.; Helge, J. W.; Rorth, M.; Midtgaard, J.; Helge, E. W.; Krustup, P.. Football training over 5 years is associated with preserved femoral bone mineral density in men with prostate cancer.. Scandinavian Journal of Medicine & Science in Sports 2018;28(Suppl 1):61-73. [DOI: ]

**Villumsen 2019**

Villumsen B.R.; Jorgensen M.G.; Frystyk J.; Hordam B.; Borre, M.. Home-based 'exergaming' was safe and significantly improved 6-min walking distance in patients with prostate cancer: a single-blinded randomised controlled trial.. BJU international 2019;124(4):600-608. [DOI: ]

**Westley 2019**

Westley, R. L.; Alexander, S.; D'aquino, A.; Murray, J.; Dearnaley, D.. Exploring the Value of a Pre-trial Outlining Exercise in the POPS Trial, which Evaluated the Localising Device ProSpare in Prostate Bed Radiotherapy. Clinical oncology 2019;31(2):e25-e25. [DOI: 10.1016/j.clon.2018.11.019]

**Wilson 2017**

Wilson R.L.; Newton R.U.; Galvao D.A.; Spry N.; Singh F.; Joseph D.; Chambers S.K.; Gardiner R.A.; Wall B.A.; Taaffe, D. R.. Contrasting exercise modes enhance muscle strength and physical function in prostate cancer survivors undertaking androgen deprivation therapy: A 12-month randomized controlled trial.. *BJU international* 2017;Conference(Journal Article);18th. [DOI: ]

**Windsor 2004**

Windsor, P. M.; Nicol, K. F.; Potter, J.. A randomized, controlled trial of aerobic exercise for treatment-related fatigue in men receiving radical external beam radiotherapy for localized prostate carcinoma. *Cancer* 2004;101(3):550-557. [DOI: 10.1002/cncr.20378 [doi]]

**Winters Stone 2015a**

Winters-Stone, Kerri M.; Dieckmann, Nathan; Maddalozzo, Gianni F.; Bennett, Jill A.; Ryan, Christopher W.; Beer, Tomasz M.. Resistance Exercise Reduces Body Fat and Insulin During Androgen-Deprivation Therapy for Prostate Cancer.. *Oncology nursing forum* 2015;42(4):348-356. [DOI: ]

**Winters Stone 2016**

Winters-Stone, Kerri M.; Lyons, Karen S.; Dobek, Jessica; Dieckmann, Nathan F.; Bennett, Jill A.; Nail, Lillian; Beer, Tomasz M.. Benefits of partnered strength training for prostate cancer survivors and spouses: results from a randomized controlled trial of the Exercising Together project.. *Journal of Cancer Survivorship* 2016;10(4):633-644. [DOI: ]

**Zopf 2015**

Zopf, Eva M.; Bloch, Wilhelm; Machtens, Stefan; Zumbe, Jurgen; Rubben, Herbert; Marschner, Stefan; Kleinhorst, Christian; Schulte-Frei, Birgit; Herich, Lena; Felsch, Moritz; Predel, Hans-Georg; Braun, Moritz; Baumann, Freerk T.. Effects of a 15-Month Supervised Exercise Program on Physical and Psychological Outcomes in Prostate Cancer Patients Following Prostatectomy: The ProRehab Study.. *Integrative Cancer Therapies* 2015;14(5):409-418. [DOI: ]

**Data and analyses**

**1 Superviseret træning vs vanlig aktivitet**

Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
1.1 Livskvalitet (quality of life) Diagnosespecifik livskvalitet	12	767	Std. Mean Difference (IV, Random, 95% CI)	0.45 [0.30, 0.59]
1.1.1 Measured with FACT-P	8	543	Std. Mean Difference (IV, Random, 95% CI)	0.40 [0.21, 0.59]
1.1.2 EORTC-QLQ-C30	4	224	Std. Mean Difference (IV, Random, 95% CI)	0.54 [0.27, 0.81]
1.2 Livskvalitet (quality of life),general livskvalitet, SF-36 totalscore	3	198	Mean Difference (IV, Random, 95% CI)	-1.60 [-3.94, 0.75]
1.3 Livskvalitet (quality of life),general livskvalitet, SF-36, physical component	4	246	Mean Difference (IV, Random, 95% CI)	-1.34 [-4.67, 1.99]
1.4 Livskvalitet (quality of life), general livskvalitet, SF-36 mental component	3	198	Mean Difference (IV, Random, 95% CI)	-3.30 [-5.74, -0.87]




1.5 Fysisk funktion (physical function) gangtest	11	612	Std. Mean Difference (IV, Random, 95% CI)	-0.45 [-0.64, -0.25]
1.6 Fysisk funktion (physical function) rejse/sætte sig test	7	404	Std. Mean Difference (IV, Random, 95% CI)	-0.33 [-0.57, -0.08]
1.7 Muskelstyrke (Strength)	16	968	Std. Mean Difference (IV, Random, 95% CI)	0.46 [0.26, 0.65]
1.8 Vo2 max (Vo2 peak)	7	406	Mean Difference (IV, Random, 95% CI)	1.76 [0.82, 2.69]
1.9 Depressions symptomer (depressive symptoms)	2	89	Std. Mean Difference (IV, Random, 95% CI)	-0.34 [-0.76, 0.08]
1.10 Frakturer (fractures) Risk diff. antal personer med	18	1071	Risk Difference (IV, Random, 95% CI)	0.00 [-0.01, 0.02]
1.10.1 Football training	2	136	Risk Difference (IV, Random, 95% CI)	0.02 [-0.05, 0.09]
1.10.2 Aerobic and/or resistance training	16	935	Risk Difference (IV, Random, 95% CI)	0.00 [-0.02, 0.02]
1.11 Frakturer (fractures) Risk ratio, antal personer med	18	1071	Risk Ratio (IV, Random, 95% CI)	1.86 [0.25, 13.99]
1.11.1 Aerobic and/or resistance training	16	935	Risk Ratio (IV, Random, 95% CI)	Not estimable
1.11.2 Football training	2	136	Risk Ratio (IV, Random, 95% CI)	1.86 [0.25, 13.99]
1.12 Træningsrelaterede skader (Exercise related injuries) risk. diff, antal personer med	16	880	Risk Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
1.13 Træningsrelaterede skader (Exercise related injuries) risk ratio, antal personer med	16	880	Risk Ratio (IV, Random, 95% CI)	6.18 [1.41, 27.14]
1.14 Frafald (dropouts) risk ratio, antal personer	19	1417	Risk Ratio (IV, Random, 95% CI)	0.74 [0.55, 1.00]
1.14.1 Exercise start after 2 months	15	1174	Risk Ratio (IV, Random, 95% CI)	0.85 [0.62, 1.15]
1.14.2 Start of exercise with-in one month	4	243	Risk Ratio (IV, Random, 95% CI)	0.36 [0.18, 0.73]
1.15 Frafald (dropouts) risk diff, antal personer. Analysen bruges til tjek af udregning af absolutte tal i MAGIC	19	1417	Risk Difference (IV, Random, 95% CI)	-0.03 [-0.07, 0.01]

**Figures**


Figure 1

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Bjerre 2019	+	+	-	-	+	+	+
Bourke 2014	+	+	-	-	+	-	+
Cormie 2015	+	+	-	-	+	+	+
Dawson 2018	+	+	-	-	+	+	+
Focht 2018	+	+	-	+	+	-	+
Galvao 2010	+	+	-	-	+	+	+
Galvao 2018	+	+	-	-	+	+	+
Harrison 2018	+	+	-	-	+	+	?
Hojan 2017	+	+	-	-	?	+	+
Ndjavera 2020	+	+	-	-	+	+	+
Newton 2020/Taaffe 2019	+	+	-	+	+	-	+
Nielsen 2015	+	?	-	-	+	+	+
Segal 2003	+	?	-	-	?	+	+
Segal 2009a	+	+	-	-	?	+	+
Segal 2009b	+	+	-	-	?	+	+




Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

**Figure 2 (Analysis 1.1)**




Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.1 Livskvalitet (quality of life) Diagnosespecifik livskvalitet.

Figure 3 (Analysis 1.2)




Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.2 Livskvalitet (quality of life),generel livskvalitet, SF-36 totalscore.

Figure 4 (Analysis 1.5)




Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.5 Fysisk funktion (physical function) gangtest.

Figure 5 (Analysis 1.6)



Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.6 Fysisk funktion (physical function) rejse/sætte sig test.

Figure 6 (Analysis 1.7)




Footnotes

- (1) Intervention: Aerobic and resistance exercise (group) , control: usual care, mean days on ADT: 6, 100% in ADT
- (2) Intervention: Resistance training in groups, control: a home-based flexibility program, mean months on ADT: 15 (intervention)...
- (3) Intervention: resistance and aerobic exercise in groups, control: usual care including advice on physical activity according to...
- (4) Intervention: Aerobic and resistance exercise in groups, control: usual care, mean months on ADT: 18 (intervention) and 10...
- (5) Intervention: resistance, aerobic, and flexibility exercises, in groups, control: usual care, median months on ADT: 2...
- (6) Intervention: Aerobic and resistance exercise, no information on groups or individual, control: usual care, ADT began 4 weeks...
- (7) Intervention: Aerobic and resistance exercises, no information on groups or individual, control: usual care, beginning ADT...
- (8) Intervention: impact loading, aerobic and resistance exercise in groups, Control: usual care (delayed exercise), mean days on...
- (9) Intervention: Strength training, no information on groups or individual, control: usual care, mean months on ADT: 9 months,...
- (10) Intervention: Resistance exercise, individual training, control: usual care, mean months on ADT: 12 (intervention) 13 (control)...
- (11) Intervention: Resistance exercise, no information on group or individual training, control: usual care, no information on...
- (12) Intervention: Aerobic exercise, no information on group or individual training, control: usual care, no information on duration of...
- (13) Intervention: resistance + aerobic training in groups, control: usual care (delayed exercise), mean months on ADT: 5...
- (14) Intervention: impact loading + resistance training in groups, control: usual care (delayed exercise), mean months on ADT: 5...
- (15) Intervention: Football (groups), control: usual care, mean months on ADT: 12 (intervention) and 18 (control), 100% in ADT
- (16) Intervention: resistance plus impact training in groups, Control: stretching and relaxation exercises, mean months on ADT: 39...

Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.7 Muskelstyrke (Strength).




Figure 7 (Analysis 1.8)




Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.8 Vo2 max (Vo2 peak).

Figure 8 (Analysis 1.9)



Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.9 Depressions symptomer (depressive symptoms).


Figure 9 (Analysis 1.10)




- (9) intervention: Aerobic and resistance exercise, no information on groups or individual, control: usual care, ADT began 4...
- (10) intervention: Aerobic (in groups) or strength training (individual), control: usual care including standard physical...
- (11) intervention: Aerobic and resistance exercises, no information on groups or individual, control: usual care, beginning...
- (12) intervention: impact loading, aerobic and resistance exercise in groups, Control: usual care (delayed exercise), mean...
- (13) intervention: Strength training, no information on groups or individual, control: usual care, mean months on ADT: 9...
- (14) intervention: Resistance, no information on group or individual training, control: usual care, no information on duration...
- (15) intervention: Aerobic exercise, no information on group or individual training, control: usual care, no information on...
- (16) intervention: Aerobic + resistance training in groups, control: usual care (delayed exercise), mean months on...
- (17) intervention: Impact loading + resistance training in groups, control: usual care (delayed exercise), mean...
- (18) intervention: resistance plus impact training in groups, Control: stretching and relaxation exercises, mean months on...

Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.10 Frakturer (fractures) Risk diff. antal personer med.


Figure 10 (Analysis 1.11)





Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.11 Frakturer (fractures) Risk ratio, antal personer med.

Figure 11 (Analysis 1.13)




Footnotes

- (1) Intervention: Aerobic and resistance exercise in groups + dietary advice and behavioral change support, control:...
- (2) Intervention: Aerobic and resistance exercise (group) , control: usual care, mean days on ADT: 6, 100% in ADT
- (3) Intervention: Resistance training in groups, control: a home-based flexibility program, mean months on ADT: 15...
- (4) Intervention: Resistance and aerobic exercise in groups, control: usual care including advice on physical activity...
- (5) Intervention: Aerobic and resistance exercise in groups, control: usual care, mean months on ADT: 18...
- (6) Intervention: resistance, aerobic, and flexibility exercises, in groups, control: usual care, median months on ADT...
- (7) Intervention: Aerobic and resistance exercise, no information on groups or individual, control: usual care, ADT...
- (8) Intervention: Aerobic (in groups) or strength training (individual), control: usual care including standard physical...
- (9) Intervention: Aerobic and resistance exercises, no information on groups or individual, control: usual care...
- (10) Intervention: Strength training, no information on groups or individual, control: usual care, mean months on ADT...
- (11) Intervention: Resistance, no information on group or individual training, control: usual care, no information on...
- (12) Intervention: Aerobic exercise, no information on group or individual training, control: usual care, no information...
- (13) Intervention: Aerobic + resistance training in groups, control: usual care (delayed exercise), mean months on...
- (14) Intervention: Impact loading + resistance training in groups, control: usual care (delayed exercise)...
- (15) Intervention: Football (groups), control: usual care, mean months on ADT: 12 (intervention) and 18 (control)...
- (16) Intervention: resistance plus impact training in groups, Control: stretching and relaxation exercises, mean...


Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.13 Træningsrelaterede skader (Exercise related injuries) risk ratio, antal personer med.

Figure 12 (Analysis 1.12)



Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.12 Træningsrelaterede skader (Exercise related injuries) risk. diff, antal personer med.

Figure 13 (Analysis 1.14)




- (10) Intervention: Resistance, no information on group or individual training, control: usual care, no information on...  
 (11) Intervention: Aerobic exercise, no information on group or individual training, control: usual care, no information...  
 (12) Intervention: Aerobic + resistance training in groups, control: usual care (delayed exercise), mean months on...  
 (13) Intervention: Impact loading + resistance training or aerobic + resistance training in groups, control: usual care...  
 (14) Intervention: Football (groups), control: usual care, mean months on ADT: 12 (intervention) and 18 (control),...  
 (15) Intervention: resistance plus impact training in groups, Control: stretching and relaxation exercises, mean...  
 (16) Intervention: Aerobic and resistance exercise (group) , control: usual care, mean days on ADT: 6, 100% in ADT...  
 (17) Intervention: Aerobic and resistance exercise, no information on groups or individual, control: usual care, ADT...  
 (18) Intervention: Aerobic and resistance exercises, no information on groups or individual, control: usual care...  
 (19) Intervention: impact loading, aerobic and resistance exercise in groups, Control: usual care (delayed exercise),...

Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.14 Frafald (dropouts) risk ratio, antal personer.

### Figure 14 (Analysis 1.15)






**Risk of Bias Legend**

(1) Intervention: football (group), control: usual care (advice on physical activity according to guidelines), median days (A) Random sequence generation (selection bias)  
 (2) Intervention: Aerobic and resistance exercise in groups + dietary advice and behavioral change support, control: usual care (B) Allocation concealment (selection bias)  
 (3) Intervention: Aerobic and resistance exercise (group), control: usual care, mean days on ADT: 6, 100% in ADT (C) Blinding of participants and personnel (performance bias)  
 (4) Intervention: Resistance training in groups, control: a home-based flexibility program, mean months on ADT: 15... (D) Blinding of outcome assessment (detection bias)  
 (5) Intervention: resistance and aerobic exercise in groups, control: usual care including advice on physical activity... (E) Incomplete outcome data (attrition bias)  
 (6) Intervention: Aerobic and resistance exercise in groups, control: usual care, mean months on ADT: 18... (F) Selective reporting (reporting bias)  
 (7) Intervention: resistance, aerobic, and flexibility exercises, in groups, control: usual care, median months on ADT... (G) Other bias  
 (8) Intervention: Aerobic and resistance exercise, no information on groups or individual, control: usual care, ADT...  
 (9) Intervention: Aerobic (in groups) or strength training (individual), control: usual care including standard physical...  
 (10) Intervention: Aerobic and resistance exercises, no information on groups or individual, control: usual care...  
 (11) Intervention: impact loading, aerobic and resistance exercise in groups, Control: usual care (delayed exercise)...  
 (12) Intervention: Strength training, no information on groups or individual, control: usual care, mean months on ADT...  
 (13) Intervention: Resistance exercise, individual training, control: usual care, mean months on ADT: 12...  
 (14) Intervention: Resistance, no information on group or individual training, control: usual care, no information on...  
 (15) Intervention: Aerobic exercise, no information on group or individual training, control: usual care, no information...  
 (16) Intervention: Aerobic + resistance training in groups, control: usual care (delayed exercise), mean months on...  
 (17) Intervention: impact loading + resistance training in groups, control: usual care (delayed exercise), mean...  
 (18) Intervention: Football (groups), control: usual care, mean months on ADT: 12 (intervention) and 18 (control)...  
 (19) Intervention: resistance plus impact training in groups, Control: stretching and relaxation exercises, mean...


Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.15 Frafall (dropouts) risk diff, antal personer. Analysen bruges til tjek af udregning af absolutte tal i MAGIC.

**Figure 15 (Analysis 1.1)**




Funnel plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.1 Livskvalitet (quality of life) Diagnosespecifik livskvalitet.

**Figure 16 (Analysis 1.5)**




Funnel plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.5 Fysisk funktion (physical function) gangtest.

**Figure 17 (Analysis 1.7)**




Funnel plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.7 Muskelstyrke (Strengt).

**Figure 18 (Analysis 1.10)**




Funnel plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1. 10 Frakturer (fractures) Risk diff. antal personer med.

**Figure 19 (Analysis 1.12)**




Funnel plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.12 Træningsrelaterede skader (Exercise related injuries) risk. diff, antal personer med.

**Figure 20 (Analysis 1.15)**



Funnel plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.15 Frafald (dropouts) risk diff, antal personer. Analysen bruges til tjek af udregning af absolutte tal i MAGIC.

Figure 21 (Analysis 1.3)



Footnotes

- (1) Intervention: football (group), control: usual care (advice on physical activity according to guidelines), median days on ADT: 620, data from ADT population only
- (2) Intervention: Aerobic and resistance exercise (group), control: usual care, mean days on ADT: 6, 100% in ADT
- (3) Intervention: Aerobic and resistance exercise in groups, control: usual care, mean months on ADT: 18 (intervention) and 10 (control), 100% in ADT
- (4) Intervention: resistance, aerobic, and flexibility exercises, in groups, control: usual care, median months on ADT: 2 (intervention) and 4 (control), 95% in ADT

Forest plot of comparison: 1 Superviseret træning vs vanlig aktivitet, outcome: 1.3 Livskvalitet (quality of life),generel livskvalitet, SF-36, physical component.